[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2195
1. Nikan M, Osborn MF, Coles AH, Godinho BM, Hall LM, Haraszti RA, Hassler MR, Echeverria D, Aronin N, Khvorova A: Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain. Mol Ther Nucleic Acids; 2016;5:e344

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain.
  • Importantly, DHA-hsiRNAs do not induce neural cell death or measurable innate immune activation following administration of concentrations over 20 times above the efficacious dose.
  • Thus, DHA conjugation is a novel strategy for improving siRNA activity in mouse brain, with potential to act as a new therapeutic platform for the treatment of neurodegenerative disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28131259.001).
  • [Journal-full-title] Molecular therapy. Nucleic acids
  • [ISO-abbreviation] Mol Ther Nucleic Acids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; drug delivery / neurodegenerative disease / siRNA
  •  go-up   go-down


2. Ogawa R, Akaishi S: Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders. Med Hypotheses; 2016 Nov;96:51-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathogenesis of these scars clearly involves local conditions such as delayed wound healing, wound depth, and the tension of the skin around the scars.
  • Scar severity is also shaped by interactions between these local factors and genetic and systemic factors such as hypertension and sex hormones.
  • Our studies show that tension on the skin around the wound results in prolonged and/or repeated bouts of inflammation in the reticular layer of the dermis and that this inflammation generates abnormal numbers of blood vessels (as well as collagen and nerve fibers) in the dermal reticular layer.
  • We hypothesize that local factors, such as the mechanobiology of the dermis and blood vessels, along with genetic and systemic factors promote pathological scar development by inducing endothelial dysfunction (i.e., vascular hyperpermeability) during the inflammatory stage of wound healing.
  • Evidence for this hypothesis includes the fact that all effective treatments of keloids, namely, radiotherapy, compression therapy, steroid administration, and long-pulsed Nd:YAG laser therapy, act, at least partly, by suppressing blood vessels.
  • Thus, primary scars are caused by congenital endothelial dysfunction (e.g., a mutation prevents endothelial gaps from closing smoothly) while secondary scars are caused by endothelial dysfunction that results from aging, arterial sclerosis, and/or repeated/very strong local mechanical forces.
  • Thus, abnormal blood vessel regulation may underlie keloid and hypertrophic scar pathogenesis, which suggests that inhibiting abnormal angiogenesis and vascular hyperpermeability may be an important therapeutic approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.
  • (PMID = 27959277.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Shou K, Niu Y, Zheng X, Ma Z, Jian C, Qi B, Hu X, Yu A: Enhancement of Bone-Marrow-Derived Mesenchymal Stem Cell Angiogenic Capacity by NPWT for a Combinatorial Therapy to Promote Wound Healing with Large Defect. Biomed Res Int; 2017;2017:7920265

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of Bone-Marrow-Derived Mesenchymal Stem Cell Angiogenic Capacity by NPWT for a Combinatorial Therapy to Promote Wound Healing with Large Defect.
  • Negative pressure wound therapy (NPWT) has been demonstrated to be effective for enhancing wound healing, especially for the promotion of angiogenesis within wounds.
  • Here we utilized combinatory strategy using the transplantation of BMSCs and NPWT to investigate whether this combinatory therapy could accelerate angiogenesis in wounds.
  • In vivo, rat full-thickness cutaneous wounds treated with BMSCs combined with NPWT exhibited better viability of the cells and enhanced angiogenesis and maturation of functional blood vessels than did local BMSC injection or NPWT alone.
  • Expression of angiogenesis markers (NG2, VEGF, CD31, and <i>α</i>-SMA) was upregulated in wounds treated with combined BMSCs with NPWT.
  • Our data suggest that NPWT may act as an inductive role to enhance BMSCs angiogenic capacity and this combinatorial therapy may serve as a simple but efficient clinical solution for complex wounds with large defects.
  • [MeSH-major] Mesenchymal Stem Cell Transplantation. Mesenchymal Stromal Cells / cytology. Negative-Pressure Wound Therapy. Neovascularization, Physiologic. Wound Healing
  • [MeSH-minor] Animals. Biomarkers / metabolism. Cell Differentiation. Cell Proliferation. Cell Shape. Cell Survival. Combined Modality Therapy. Cytokines / metabolism. Male. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):948-53 [17521616.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] Tissue Eng. 2007 Dec;13(12):3003-10 [17988192.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):738-46 [10471461.001]
  • [Cites] Ostomy Wound Manage. 2004 Apr;50(4B Suppl):3S-27S [15311482.001]
  • [Cites] Biomaterials. 2015 Jun;53:58-75 [25890707.001]
  • [Cites] Stem Cells. 2010 May;28(5):905-15 [20474078.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1704-10 [16291063.001]
  • [Cites] Wound Repair Regen. 2011 Nov;19(6):727-33 [22092843.001]
  • [Cites] Int Wound J. 2009 Aug;6 Suppl 1:1-26 [19614789.001]
  • [Cites] J Biomech. 2010 Apr 19;43(6):1176-81 [20022602.001]
  • [Cites] J Vasc Surg. 2006 Jan;43(1):134-41 [16414400.001]
  • [Cites] Tissue Eng. 2007 Jun;13(6):1299-312 [17518741.001]
  • [Cites] PLoS One. 2014 Sep 12;9(9):e107339 [25216182.001]
  • [Cites] J Bone Joint Surg Am. 2014 Aug 20;96(16):1378-85 [25143498.001]
  • [Cites] Injury. 2014 May;45(5):890-3 [22377275.001]
  • [Cites] Ann Plast Surg. 2013 Jan;70(1):23-9 [23249474.001]
  • [Cites] Am J Physiol Cell Physiol. 2009 Mar;296(3):C535-43 [19109527.001]
  • [Cites] Ann Vasc Surg. 2003 Nov;17(6):645-9 [14534844.001]
  • [Cites] Stem Cells. 2008 May;26(5):1307-14 [18308943.001]
  • [Cites] Ann Surg. 2011 Feb;253(2):402-9 [21217515.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):782-8 [18355797.001]
  • [Cites] Cytotherapy. 2011 Jul;13(6):705-11 [21284564.001]
  • [Cites] J Dermatol. 2003 Aug;30(8):596-601 [12928528.001]
  • [Cites] J Bone Joint Surg Br. 2007 Oct;89(10 ):1382-6 [17957083.001]
  • [Cites] Curr Opin Hematol. 2006 Nov;13(6):419-25 [17053453.001]
  • [Cites] Ann Plast Surg. 2001 Nov;47(5):547-51 [11716268.001]
  • [Cites] Acta Biomater. 2015 Dec;28:64-75 [26432440.001]
  • [Cites] J Control Release. 2011 Jun 30;152(3):411-7 [21435363.001]
  • [Cites] Biomaterials. 2015;53:379-91 [25890736.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2648-59 [17615264.001]
  • [Cites] Stem Cells Dev. 2011 Aug;20(8):1297-308 [21303266.001]
  • [Cites] Am J Cardiol. 2004 Jul 1;94(1):92-5 [15219514.001]
  • [Cites] Stem Cell Res Ther. 2010 Sep 24;1(4):30 [20863417.001]
  • [Cites] Arch Dermatol. 2003 Apr;139(4):510-6 [12707099.001]
  • [Cites] Expert Rev Med Devices. 2006 May;3(3):373-85 [16681458.001]
  • [Cites] Am J Surg. 2011 Apr;201(4):544-56 [21421104.001]
  • [Cites] Stem Cells Dev. 2009 Nov;18(9):1299-308 [19508152.001]
  • [Cites] Ostomy Wound Manage. 2000 Aug;46(8):28-32, 34 [11189545.001]
  • [Cites] Wound Repair Regen. 2009 Mar-Apr;17(2):200-5 [19320888.001]
  • (PMID = 28243602.001).
  • [ISSN] 2314-6141
  • [Journal-full-title] BioMed research international
  • [ISO-abbreviation] Biomed Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines
  •  go-up   go-down


Advertisement
4. Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Péter Z, Rókusz L, Schneider F, Szalay F, Tornai I, Werling K, Makara M: [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016]. Orv Hetil; 2017 Feb;158(Suppl 1):3-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary.
  • This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents.
  • Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver.
  • Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure.
  • Interferon-free treatments and shorter therapy durations are preferred. Orv.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28218867.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Keywords] NOTNLM ; direct acting antiviral drug / direkt ható antivirális szer / genotype / genotípus / hepatitis C virus / hepatitis C-vírus / hepatocellular carcinoma / interferon / liver cirrhosis / májrák / májzsugor / polimerázgátló / polymerase inhibitor / protease inhibitor / proteázgátló / replication complex inhibitor / replikációskomplex-gátló / viral hepatitis / vírushepatitis
  •  go-up   go-down


5. Aznar MA, Tinari N, Rullán AJ, Sánchez-Paulete AR, Rodriguez-Ruiz ME, Melero I: Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally. J Immunol; 2017 Jan 01;198(1):31-39

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.
  • : Immune mechanisms have evolved to cope with local entry of microbes acting in a confined fashion but eventually inducing systemic immune memory.
  • Indeed, in situ delivery of a number of agents into tumors can mimic in the malignant tissue the phenomena that control intracellular infection leading to the killing of infected cells.
  • Intratumoral therapy with pathogen-associated molecular patterns or recombinant viruses is being tested in the clinic.
  • Local delivery means less systemic toxicity while focusing the immune response on the malignancy and the affected draining lymph nodes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 by The American Association of Immunologists, Inc.
  • (PMID = 27994166.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Rupreht RR, Mozetič-Francky B, Francky A, Matis M, Škoberne M, Galvani V, Malovrh T, Kotnik V, Šerbec VČ: Murine monoclonal antibodies directed against human recombinant Macrophage Migration Inhibitory Factor. Pflugers Arch; 2000 Jan;440(Suppl 1):R078-R080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Macrophage Migration Inhibitory Factor (MIF) is a crucial component of the immune system acting together with glucocorticosteroids to regulate immunity and inflammation.
  • Due to the newest findings that a local MIF expression is up regulated in allograft rejection and in glomerulonephritis, an interest in MIF research is increasing and is focused on possibilities of anti-MIF treatment.In the present work new murine monoclonal antibodies (MAbs) directed against human recombinant MIF (hrMIF) are described. hrMIF protein used for the immunisation was tested for its biological activity and has evident macrophage migration inhibitory activity.
  • Anti-MIF MAb designated as Ml inhibited MIF activity in the test, which was performed in the 48 well Boyden chamber system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28008489.001).
  • [ISSN] 1432-2013
  • [Journal-full-title] Pflugers Archiv : European journal of physiology
  • [ISO-abbreviation] Pflugers Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Key words MIF / anti-MIF MAb / anti-MIF therapy / immune response
  •  go-up   go-down


7. Mukherjee M, Lim HF, Thomas S, Miller D, Kjarsgaard M, Tan B, Sehmi R, Khalidi N, Nair P: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy Asthma Clin Immunol; 2017;13:2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy.
  • CASE PRESENTATION: A 62-year old woman diagnosed with severe eosinophilic asthma showed poor response to Mepolizumab therapy (100 mg subcutaneous dose/monthly) and subsequent worsening of symptoms.
  • The treatment response to Mepolizumab was monitored using both blood and sputum eosinophil counts.
  • The latter was superior in assessing deterioration in symptoms, suggesting that normal blood eosinophil count may not always indicate amelioration or adequate control of the ongoing eosinophil-driven disease process.
  • This perplexing situation of persistent airway eosinophilia and increased steroid insensitivity despite an anti-eosinophil therapy can be explained if the administered dose of the mAb was inadequate in comparison to the target antigen.
  • The resultant immune complexes could act as 'cytokine depots', protecting the potency of the 'bound' IL-5, thereby sustaining the eosinophilic inflammation within the target tissue.
  • CONCLUSIONS: While anti-IL5 mAb therapy is an exciting novel option to treat patients with severe asthma, there is the rare possibility of worsening of asthma as observed in this case study, due to local autoimmune mechanisms precipitated by potential inadequate airway levels of the monoclonal antibody.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28070196.001).
  • [ISSN] 1710-1484
  • [Journal-full-title] Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
  • [ISO-abbreviation] Allergy Asthma Clin Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Autoantibodies / Autoimmune / Eosinophilic asthma / IL-5 / Immune complex / Mepolizumab / Sputum
  •  go-up   go-down


8. Cheng P, Zeng W, Li L, Huo D, Zeng L, Tan J, Zhou J, Sun J, Liu G, Li Y, Guan G, Wang Y, Zhu C: PLGA-PNIPAM Microspheres Loaded with the Gastrointestinal Nutrient NaB Ameliorate Cardiac Dysfunction by Activating Sirt3 in Acute Myocardial Infarction. Adv Sci (Weinh); 2016 Dec;3(12):1600254

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nutrients supplied by the blood are the main source of cellular energy for cardiomyocytes.
  • Sodium butyrate (NaB), a gastrointestinal nutrient, is a short-chain fatty acid (butyric acid) that may act as an energy source in AMI therapy.
  • Poly(lactic-co-glycolic acid)-Poly (<i>N</i>-isopropylacrylamide) microspheres loaded with NaB (PP-N) are synthesized to prolong the release of NaB and are injected into ischemic zones in a Sprague-Dawley rat AMI model.
  • The results indicate that NaB, acting as a nutrient, can protect cardiomyocytes in AMI.
  • These results suggest that the gastrointestinal nutrient NaB may be a new therapy for AMI treatment, and PP-N may be the ideal therapeutic regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27981013.001).
  • [Journal-full-title] Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  • [ISO-abbreviation] Adv Sci (Weinh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Sirt3 / fatty acids / ischemia / microspheres
  •  go-up   go-down


9. McArthur TA, Narducci CA, Lander PH, Lopez-Ben R: Percutane Image-Guided Cryoablation of Painful Osseous Metastases: A Retrospective Single-Center Review. Curr Probl Diagn Radiol; 2016 Nov 10;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this institutional review board-approved, health insurance portability and accountability act-compliant study, we retrospectively searched our department׳s picture archiving system for patients who underwent computed tomography (CT)-guided percutaneous cryoablation for treatment of painful metastatic osseous disease over a 6-year period (1/1/2005-12/31/2011).
  • The preprocedure and postprocedure images and imaging reports, primary tumor type, CT-guided cryoablation procedure details, treated tumor response, immediate and 3-month postprocedure complications, reported pain response to cryoablation, postprocedural tumor imaging characteristics, and imaging response of noncryoablated systemically treated metastatic lesions were reviewed in patients with metastatic osseous disease who underwent cryoablation.
  • RESULTS: All 16 patients reported improvement in pain within 1 week after the procedure and at 3-month clinical follow-up.
  • A total of 6.2% had tumor growth and 93.8% had tumor arrest or shrinkage on follow-up CT, although all study patients had progression of noncryoablated metastases at other sites despite systemic therapy.
  • A total of 62.5% of patients with posttreatment contrasted CT demonstrated marginal enhancement at the ablation site, although only single patient had interval growth.
  • CONCLUSION: Most of our patients had tumor arrest or shrinkage on follow-up imaging, despite progression of noncryoablated metastases treated with preprocedure and postprocedure systemic therapy.
  • Radiation therapy, chemotherapy, and analgesics have a moderate failure rate and require repeat treatments where quality of life is the foremost objective.
  • CT-guided cryoablation is a safe palliative treatment to reduce pain in patients with painful osseous metastatic disease, achieve effective local tumor control, and in some cases, provide a curative option for a target lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier Inc. All rights reserved.
  • (PMID = 28034477.001).
  • [ISSN] 1535-6302
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Pissulin CN, de Souza Castro PA, Codina F, Pinto CG, Vechetti-Junior IJ, Matheus SM: GaAs laser therapy reestablishes the morphology of the NMJ and nAChRs after injury due to bupivacaine. J Photochem Photobiol B; 2017 Feb;167:256-263

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GaAs laser therapy reestablishes the morphology of the NMJ and nAChRs after injury due to bupivacaine.
  • BACKGROUND: Local anesthetics are used to relieve pre- and postoperative pain, acting on both sodium channels and nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (NMJ).
  • Bupivacaine acts as a non-competitive antagonist and has limitations, such as myotoxicity, neurotoxicity, and inflammation.
  • Low-level laser therapy (LLLT) has anti-inflammatory, regenerative, and analgesic effects.
  • Next, the animals were divided into a Control group (C) and a Laser group (LLLT).
  • The maximum diameters of the NMJs were lower in the Bupi (15.048±1.985) and LLLT/Bupi subgroups (15.456±1.983) compared to the Cl (18.502±2.058) and LLLT/Cl subgroups (19.356±2.522) (p<0.05).
  • There was an increase in the perimeter of the LLLT/Bupi subgroup (150.33) compared to the Bupi subgroup (74.69) (p<0.01) observed by confocal microscopy.
  • There was also an increase in the relative planar area of the NMJ after LBI (8.75) compared to CBupi (4.80) (p<0.01).
  • There was an increase in protein expression of the ε subunit after application of LLLT (13.055) compared to Bupi (0.251) (p<0.01).
  • Taken together, the present experiments indicate that there was a positive association of the α and γ subunits (p<0.05).
  • CONCLUSIONS: These results demonstrate that LLLT at the dose used in this study reduced structural alterations in the NMJ and molecular changes in nAChRs triggered by bupivacaine, providing important data supporting the use of LLLT in therapeutic protocols for injuries triggered by local anesthetics.
  • [MeSH-major] Anesthetics, Local / adverse effects. Bupivacaine / adverse effects. Lasers, Semiconductor. Low-Level Light Therapy. Neuromuscular Junction / radiation effects. Receptors, Nicotinic / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier B.V. All rights reserved.
  • (PMID = 28088107.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Receptors, Nicotinic; Y8335394RO / Bupivacaine
  • [Keywords] NOTNLM ; Bupivacaine / Low-level light therapy / Neuromuscular junction / Nicotinic acetylcholine receptor
  •  go-up   go-down


11. Aldridge A, Dowd W, Bray J: The relative impact of brief treatment versus brief intervention in primary health-care screening programs for substance use disorders. Addiction; 2017 Feb;112 Suppl 2:54-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND PARTICIPANTS: A total of 9029 patients with both baseline and follow-up interviews were identified in the US Government Performance and Results Act (GPRA) data from October 2004 and February 2008.
  • Using a propensity score framework, multiple generalized linear mixed models and a local linear matching method with a difference in difference estimator, patients from the BI group that resemble BT patients were used to determine the relative treatment effect of BT.
  • A total of 3218 of these US patients with baseline and follow-up interviews were used in the final analysis sample after the propensity score-matching procedure (1448 patients assigned to a BI service category and 1770 assigned to a BT service category).
  • BT was found to reduce the frequency of use of illicit drugs at follow-up by 0.634 days more than BI (P < 0.05).
  • Higher severity patients assigned to BT had a decrease in days of illicit drug use of 1.765 (P < 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Society for the Study of Addiction.
  • (PMID = 28074568.001).
  • [ISSN] 1360-0443
  • [Journal-full-title] Addiction (Abingdon, England)
  • [ISO-abbreviation] Addiction
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Brief intervention / SBI / SBIRT / brief therapy / brief treatment / illicit drugs / propensity score / quasi-experimental
  •  go-up   go-down


12. Butler SM: Changes to radiotherapy utilisation in Western NSW after the opening of a local service. J Med Radiat Sci; 2017 Feb 03;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes to radiotherapy utilisation in Western NSW after the opening of a local service.
  • INTRODUCTION: In 2011, the first radiotherapy centre in Western NSW Local Health District (WNSWLHD) was opened in the city of Orange.
  • METHODS: Data were collected on WNSWLHD patients, 17 years of age and above, who received radiotherapy in either 2010 or 2012 in New South Wales (NSW) or Australian Capital Territory (ACT).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.
  • (PMID = 28160454.001).
  • [ISSN] 2051-3909
  • [Journal-full-title] Journal of medical radiation sciences
  • [ISO-abbreviation] J Med Radiat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Health services / patient access / radiation oncology / rural / travel distance
  •  go-up   go-down


13. Khlopas A, Elmallah RK, Chughtai M, Yakubek GA, Faour M, Klika AK, Higuera CA, Molloy RM, Mont MA: The Learning Curve Associated with the Administration of Intra-Articular Liposomal Bupivacaine for Total Knee Arthroplasty: A Pilot Study. Surg Technol Int; 2017 Feb 07;30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Liposomal bupivacaine is a long-acting, local, injectable anesthetic that is used to potentially mitigate post-operative pain after total knee arthroplasty (TKA).
  • Pain scores were calculated using the visual analogue scale (VAS), obtained from the first post-operative physical therapy note.
  • We used an ANOVA test for continuous and X2-square test for categorical variables.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28182826.001).
  • [ISSN] 1090-3941
  • [Journal-full-title] Surgical technology international
  • [ISO-abbreviation] Surg Technol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Chanawong A, Mackenzie PI, McKinnon RA, Hu DG, Meech R: Exemestane and Its Active Metabolite 17-hydroexemestane Induce UDP-glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells. J Pharmacol Exp Ther; 2017 Apr 12;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exemestane (EXE) is an aromatase inhibitor indicated for endocrine therapy of breast cancer in post-menopausal women.
  • This result is consistent with previous reports that 17-HE can act as an AR ligand.
  • The upregulation of UGT2B17 by EXE and 17-HE in breast cancer cells might enhance the local metabolism of 17-HE as well as that of endogenous androgens, hence impacting on treatment outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The American Society for Pharmacology and Experimental Therapeutics.
  • (PMID = 28404691.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; UDP Glucuronosyltransferase / aromatase inhibitors / breast cancer / gene regulation / steroids
  •  go-up   go-down


15. Kim DW, Cho SH: Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine. Allergy Asthma Immunol Res; 2017 Jul;9(4):299-306

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Defining endotypes can help clinicians predict disease prognosis, select subjects suitable for a specific therapy, and assess risks for comorbid conditions, including asthma.
  • Thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33, which are mainly secreted by epithelial cells in response to external stimuli, act on type 2 ILCs and T helper 2 (Th2) cells, inducing IL-4, IL-5, and IL-13.
  • Local immunoglobulin E (IgE) production is also a signature event in nasal polyps (NP).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease.
  • (PMID = 28497916.001).
  • [ISSN] 2092-7355
  • [Journal-full-title] Allergy, asthma & immunology research
  • [ISO-abbreviation] Allergy Asthma Immunol Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; Nasal polyps / biologicals / chronic rhinosinusitis / cytokines / endotypes / phenotypes
  •  go-up   go-down


16. Fu Y, Karbaat L, Wu L, Leijten JCH, Both S, Karperien M: Trophic effects of mesenchymal stem cells in tissue regeneration. Tissue Eng Part B Rev; 2017 May 10;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesenchymal stem cells (MSCs) are considered to hold great therapeutic value for cell-based therapy and for tissue regeneration in particular.
  • These bioactive factors have diverse actions like modulating the local immune system, enhancing angiogenesis, preventing cell apoptosis, and stimulating survival, proliferation and differentiation of resident tissue specific cells.
  • We will also highlight the various underlying mechanisms employed by MSCs to act as trophic mediators.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28490258.001).
  • [ISSN] 1937-3376
  • [Journal-full-title] Tissue engineering. Part B, Reviews
  • [ISO-abbreviation] Tissue Eng Part B Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Wolfensberger TJ: Macular Edema - Rationale for Therapy. Dev Ophthalmol; 2017;58:74-86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macular Edema - Rationale for Therapy.
  • When macular edema is caused by a generalized health problem such as diabetes, high blood pressure, or generalized inflammatory conditions, treatment of these generalized diseases can in many cases cure macular edema directly.
  • In ocular diseases, the local exudation of fluid from blood vessels is governed by Starling's law as well as by intricate cellular mechanisms linked to the tight junctions in the inner and outer blood-retinal barrier.
  • Drugs used in clinical practice, such as nonsteroidal anti-inflammatory drugs, corticosteroids, carbonic anhydrase inhibitors, and anti-vascular endothelial growth factor agents, all act in one way or another through these cellular mechanisms.
  • Successful surgical treatment of macular edema using vitrectomy and peeling relies, apart from the evident release of vitreomacular traction, on many other cellular and biochemical mechanisms activated by the surgery such as oxygenation of the inner retina, removal of the posterior hyaloid as a growth factor sink, and possible Müller cell remodeling with fluid redirection after internal limiting membrane peeling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28351053.001).
  • [ISSN] 1662-2790
  • [Journal-full-title] Developments in ophthalmology
  • [ISO-abbreviation] Dev Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Ogawa R: Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis. Int J Mol Sci; 2017 Mar 10;18(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The latter is characterized by continuous and histologically localized inflammation.
  • As a result, the reticular layer of keloids and hypertrophic scars contains inflammatory cells, increased numbers of fibroblasts, newly formed blood vessels, and collagen deposits.
  • These proinflammatory stimuli include a variety of local, systemic, and genetic factors.
  • At present, physicians cannot (or at least find it very difficult to) control systemic and genetic risk factors of keloids and hypertrophic scars.
  • However, they can use a number of treatment modalities that all, interestingly, act by reducing inflammation.
  • They include corticosteroid injection/tape/ointment, radiotherapy, cryotherapy, compression therapy, stabilization therapy, 5-fluorouracil (5-FU) therapy, and surgical methods that reduce skin tension.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 2015 Sep;136(3):397e-398e [26020701.001]
  • [Cites] Wound Repair Regen. 2015 Mar-Apr;23(2):213-21 [25728259.001]
  • [Cites] Int Wound J. 2014 Oct;11(5):517-22 [23173565.001]
  • [Cites] HNO. 2006 Nov;54(11):893-904; quiz 905 [17041777.001]
  • [Cites] Oncol Rep. 2015 Apr;33(4):1753-62 [25634241.001]
  • [Cites] BioDrugs. 2005;19(6):363-81 [16392889.001]
  • [Cites] Ann Plast Surg. 2008 Apr;60(4):445-51 [18362577.001]
  • [Cites] Stem Cells Int. 2016;2016:6937976 [26839566.001]
  • [Cites] Plast Reconstr Surg Glob Open. 2015 Jan 08;2(12):e272 [25587506.001]
  • [Cites] Curr Opin Cardiol. 1994 Sep;9(5):619-26 [7987043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):167-72 [11316560.001]
  • [Cites] J Surg Res. 2003 Aug;113(2):208-16 [12957131.001]
  • [Cites] Zhonghua Zheng Xing Wai Ke Za Zhi. 2007 Mar;23(2):137-40 [17554881.001]
  • [Cites] Int Wound J. 2016 Dec 19;:null [27995750.001]
  • [Cites] Plast Reconstr Surg. 2013 Oct;132(4):621e-630e [24076710.001]
  • [Cites] Biomed Rep. 2013 Nov;1(6):833-836 [24649037.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1126-32 [15140214.001]
  • [Cites] J Nippon Med Sch. 2011;78(2):68-76 [21551963.001]
  • [Cites] Burns. 2016 Mar;42(2):356-65 [26739087.001]
  • [Cites] Nat Genet. 2010 Sep;42(9):768-71 [20711176.001]
  • [Cites] Brachytherapy. 2014 Sep-Oct;13(5):508-13 [24556345.001]
  • [Cites] Plast Reconstr Surg. 1975 Oct;56(4):450-3 [1099591.001]
  • [Cites] Trends Mol Med. 2013 Sep;19(9):555-64 [23790684.001]
  • [Cites] Dermatol Clin. 1997 Jul;15(3):419-29 [9189679.001]
  • [Cites] J Nippon Med Sch. 2016;83(2):46-53 [27180789.001]
  • [Cites] J Trauma. 1983 Oct;23(10):895-8 [6632013.001]
  • [Cites] Med Hypotheses. 2016 Nov;96:51-60 [27959277.001]
  • [Cites] Wound Repair Regen. 2012 Mar-Apr;20(2):149-57 [22332721.001]
  • [Cites] J Invest Dermatol. 2014 Jul;134(7):2041-3 [24496234.001]
  • (PMID = 28287424.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Interleukins
  • [Keywords] NOTNLM ; hypertrophic scar / keloid / radiation / steroid tape / surgery
  •  go-up   go-down


19. Rutter GA, Hodson DJ, Chabosseau P, Haythorne E, Pullen TJ, Leclerc I: Local and regional control of calcium dynamics in the pancreatic islet. Diabetes Obes Metab; 2017 May 03;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local and regional control of calcium dynamics in the pancreatic islet.
  • Ca<sup>2+</sup> is the key intracellular regulator of insulin secretion, acting in the beta cell as the ultimate trigger for exocytosis.
  • In response to high glucose, ATP-sensitive K<sup>+</sup> channel closure and plasma membrane depolarisation engage a sophisticated machinery to drive pulsatile cytosolic Ca<sup>2+</sup> changes.
  • Voltage-gated Ca<sup>2+</sup> channels, Ca<sup>2+</sup> -activated K<sup>+</sup> channels and Na<sup>+</sup> /Ca<sup>2+</sup> exchange all play important roles.
  • The use of targeted Ca<sup>2+</sup> probes has revealed that during each cytosolic Ca<sup>2+</sup> pulse, uptake of Ca<sup>2+</sup> by mitochondria, endoplasmic reticulum (ER), secretory granules and lysosomes fine-tune cytosolic Ca<sup>2+</sup> dynamics and control organellar function.
  • For example, changes in the expression of the Ca<sup>2+</sup> binding protein Sorcin appear to provide a link between ER Ca<sup>2+</sup> levels and ER stress, affecting beta cell function and survival.
  • Across the islet, intercellular communication between highly interconnected "hubs", which act as pacemaker beta cells, and subservient "followers", ensures efficient insulin secretion.
  • New insights into the control of both the intra- and intercellular Ca<sup>2+</sup> dynamics may thus shed light on T2D pathology and provide novel opportunities for therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 28466490.001).
  • [ISSN] 1463-1326
  • [Journal-full-title] Diabetes, obesity & metabolism
  • [ISO-abbreviation] Diabetes Obes Metab
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; Ca2+ / connectivity / imaging / insulin / organelle
  •  go-up   go-down


20. Davis EL, Deane FP, Lyons GCB, Barclay GD: Is higher acceptance associated with less anticipatory grief among patients in palliative care? J Pain Symptom Manage; 2017 May 04;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acceptance based interventions from approaches like Acceptance and Commitment Therapy (ACT) have demonstrated effectiveness in helping people cope with a range of life challenges.
  • OBJECTIVES: To assess the relationships between acceptance, anticipatory grief, anxiety and depression amongst patients in palliative care.
  • RESULTS: Correlations revealed that acceptance had a strong relationship with anticipatory grief, anxiety and depression.
  • A hierarchical regression analysis on anticipatory grief showed that acceptance was the largest predictor and accounted for an additional 13% of variance in anticipatory grief over and above anxiety and depression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier Inc.
  • (PMID = 28479414.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; acceptance / anxiety / depression / grief / palliative care
  •  go-up   go-down


21. Rajurkar SP, Singh T, Arora M, Saha S, Gayar H, Talwar N, Nettleton J: Concurrent weekly taxane (T) and radiation therapy (RT) in the adjuvant treatment of breast cancer (BrCa). J Clin Oncol; 2004 Jul 15;22(14_suppl):858

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent weekly taxane (T) and radiation therapy (RT) in the adjuvant treatment of breast cancer (BrCa).
  • : 858 Background: High-risk BrCa pts receive adriamycin(A) + cyclophosphamide(C) followed by a T given every 3 wks × 4 followed by radiation therapy (RT).
  • T is suggested to act as radiosensitisers.
  • Then they received A + C every 3 wks × 4 followed by either Paclitaxel (P)(80 mg/m<sup>2</sup>/wk) or Docetaxel (D)(30 mg/m<sup>2</sup>/wk) every wk with concurrent RT 5 days/wk for 6 wks followed by a T alone every wk for 6 wks.
  • No local recurrences have occurred.
  • CONCLUSIONS: Although there have been no local recurrences, an interruption in RT of 10 days in 22% patients is concerning.
  • At this point, we cannot recommend concurrent weekly Taxane and Radiation therapy in the adjuvant treatment of breast cancer pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014278.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Yoo ER, Perumpail RB, Cholankeril G, Jayasekera CR, Ahmed A: The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C. Telemed J E Health; 2017 Apr 04;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C.
  • PURPOSE: Recently, we reported the successful application of task-shifting to improve the management of patients with chronic hepatitis C virus (HCV) infection receiving treatment with direct-acting antiviral (DAA) agents in underserved areas of California.
  • A nonphysician healthcare provider worked in close conjunction with a hepatologist to monitor the patients during the course of antiviral therapy.
  • We exclusively used our institution-based, secured e-health portal as the means of communication with the local staff and patients in outreach clinics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28375820.001).
  • [ISSN] 1556-3669
  • [Journal-full-title] Telemedicine journal and e-health : the official journal of the American Telemedicine Association
  • [ISO-abbreviation] Telemed J E Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; e-health / healthcare access / hepatitis C virus / task-shifting / telemedicine
  •  go-up   go-down


23. Eng C, Xing Y, You YN, Chang GJ, Das P, Phillips J, Wolff RA, Rodriguez-Bigas MA, Ohinata A, Crane CH: Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective. J Clin Oncol; 2011 Feb;29(4_suppl):482

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C was evaluated with 5-FU in 2 large phase III studies (RTOG 98-11 and ACT II) to establish superiority over 5-FU/MMC.
  • RTOG 98-11 reported reduced colostomy-free survival (CFS) in the C-induction arm; no differences were noted in the ACT II study.
  • The log-rank test was used to compare OS among these subgroups.
  • After a median follow up of 8.6 years, 14 pts (8%) developed local recurrence; 11 received salvage surgery.
  • Platinum-based therapy for anal cancer appears to be an acceptable alternative to MMC and should be considered as a standard option for locally advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985490.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Obata F, Murakami T, Miyagi J, Ueda S, Inagaki T, Minato M, Ono H, Nishimura K, Shibata E, Tamaki M, Yoshimoto S, Kishi F, Kishi S, Matsuura M, Nagai K, Abe H, Doi T: A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. CEN Case Rep; 2016 Nov 21;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.
  • Patients with mixed cryoglobulinemic nephropathy who have a rapidly progressive glomerulonephritis should receive immunosuppressive therapy.
  • After disease stabilization, patients should receive concurrent therapy for the underlying HCV infection.
  • The standard therapy of a chronic HCV infection is IFN monotherapy or IFN combined with ribavirin; however, after the introduction of direct-acting antivirals (DAAs), the standard therapy for patients with HCV genotype 1 has dramatically changed.
  • We report a case of HCV-associated cryoglobulinemic membranoproliferative glomerulonephritis (MPGN) successfully treated by daclatasvir and asunaprevir, which are IFN-free DAAs for HCV, in combination with angiotensin II receptor blocker without immunosuppressive therapy.
  • Blood examination revealed a high copy number of HCV-RNA (6.4 log IU/mL, type 1), cryoglobulinemia, paraproteinemia of IgM-κ, and hypocomplementemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28509128.001).
  • [Journal-full-title] CEN case reports
  • [ISO-abbreviation] CEN Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Cryoglobulinemic membranoproliferative glomerulonephritis / Hepatitis C virus / Interferon-free direct-acting antiviral agents
  •  go-up   go-down


25. Li X, Chan NS, Tam AW, Hung IFN, Chan EW: Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis; 2017 May 17;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.
  • The purpose of this investigation was to evaluate the budget impact and cost-effectiveness of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection in Hong Kong.
  • A decision analytic model was developed to compare short-term costs and health outcomes of patients with chronic HCV genotype 1 infection in Hong Kong who were treated with an interferon (INF)-based treatment (dual therapy of pegylated interferon and ribavirin) or DAA-based treatments (sofosbuvir or ledipasvir/sofosbuvir or ombitasvir/paritaprevir/ritonavir plus dasabuvir).
  • The incremental cost-effective ratios of DAA-based treatments ranged from $9724 to $29,189 per treatment success, which were all below the cost-effectiveness threshold of local GDP per capita ($42,423 in 2015).
  • Introducing DAAs to the public hospital formulary yields a considerable budget increase but is still economically favorable to the local government.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28516201.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Verschuere J, Decroo T, Lim D, Kindermans JM, Nguon C, Huy R, Alkourdi Y, Peeters Grietens K, Gryseels C: Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study. Malar J; 2017 Feb 17;16(1):81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study.
  • BACKGROUND: Despite emerging drug resistance in Cambodia, artemisinin-based combination therapy (ACT) is still the most efficacious therapy.
  • ACT is available free of charge in the Cambodian public sector and at a subsidized rate in the private sector.
  • Initial treatment options consist of cheap and accessible home-based care (manual therapy, herbs and biomedical medication) targeting single symptoms.
  • CONCLUSIONS: Cambodian perceptions of illness that focus on single symptoms and their perceived severity may lead to the identification of one or multiple illnesses at the same time, rarely suspecting malaria from the start and implying different patterns of health seeking behaviour and treatment choice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2014 Jul 31;371(5):411-23 [25075834.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):455-67 [19641202.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2006 Nov;100(11):1019-24 [16765399.001]
  • [Cites] PLoS One. 2013 Nov 11;8(11):e80343 [24244678.001]
  • [Cites] Parassitologia. 1998 Jun;40(1-2):217-29 [9653747.001]
  • [Cites] Malar J. 2008 May 29;7:96 [18510724.001]
  • [Cites] Malar J. 2014 Oct 06;13:394 [25288380.001]
  • [Cites] Sci Rep. 2015 Nov 23;5:16837 [26593245.001]
  • [Cites] Malar J. 2016 May 20;15(1):282 [27206729.001]
  • [Cites] BMC Public Health. 2007 Sep 24;7:262 [17892564.001]
  • [Cites] Trop Med Int Health. 2004 Dec;9(12):1241-6 [15598255.001]
  • [Cites] Microbiol Spectr. 2016 Jun;4(3):null [27337450.001]
  • [Cites] Science. 2010 May 14;328(5980):866-71 [20466925.001]
  • [Cites] Malar J. 2016 Aug 26;15(1):434 [27562347.001]
  • [Cites] Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):39-50 [25897063.001]
  • [Cites] Lancet Infect Dis. 2012 Nov;12(11):820-2 [22940026.001]
  • [Cites] Clin Infect Dis. 2010 Dec 1;51(11):e82-9 [21028985.001]
  • [Cites] Trop Med Int Health. 2001 Nov;6(11):845-8 [11703837.001]
  • [Cites] Malar J. 2014 Sep 30;13:385 [25266007.001]
  • [Cites] Malar J. 2015 Jun 20;14:252 [26088924.001]
  • [Cites] Lancet Infect Dis. 2002 Apr;2(4):209-18 [11937421.001]
  • (PMID = 28212641.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Sugarbaker PH: Strategies to improve local control of resected pancreas adenocarcinoma. Surg Oncol; 2017 Mar;26(1):63-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to improve local control of resected pancreas adenocarcinoma.
  • The disease has an anatomic location that makes it difficult for the surgeon to maintain adequate margins of resection and prevent tumor spillage at the time of resection.
  • A regional chemotherapy treatment that consists of hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine and long-term normothermic intraperitoneal chemotherapy (NIPEC-LT) gemcitabine for 6 months postoperatively is suggested as a new treatment that has demonstrated decreases in local-regional failure and promises to more adequately target micrometastases in the peritoneal space, in the liver and lymph nodes.
  • Long-term intraperitoneal gemcitabine may act on micrometastases in the liver through absorption into the portal vein blood and the lymph nodes as a result of gemcitabine absorption by subperitoneal lymphatic channels.
  • The use of HIPEC and NIPEC-LT gemcitabine may improve local control of resected pancreas cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28317586.001).
  • [ISSN] 1879-3320
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Gemcitabine / Hyperthermic perioperative chemotherapy (HIPEC) / Intraoperative radiation therapy / Intraperitoneal port / Pancreaticoduodenectomy / Total pancreatectomy / Whipple procedure
  •  go-up   go-down


28. Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P: Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer; 2017;5:4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
  • Histology studies of regressing tumors at 1 week after therapy, revealed extensive tumor destruction and a heavy infiltration of CD45<sup>+</sup> leukocytes including F4/80<sup>+</sup> macrophages, CD8<sup>+</sup> cytotoxic T cells and CD4<sup>+</sup> helper T cells.
  • The generation of tumor-specific T cells by combined therapy was confirmed by IFN-γ secretion in tumor-stimulated splenocytes.
  • CONCLUSIONS: These findings suggest that cancer vaccine given prior to local tumor irradiation augments an immune response targeted at tumor antigens that results in specific anti-tumor immunity.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28116088.001).
  • [ISSN] 2051-1426
  • [Journal-full-title] Journal for immunotherapy of cancer
  • [ISO-abbreviation] J Immunother Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; IL-2 / MUC1 / MVA vector / Radiation / Renal Cell Carcinoma
  •  go-up   go-down


29. Lusk KA, Snoga JL, Benitez RM, Sarbacker GB: Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding. J Pharm Pract; 2017 Jan 01;:897190017707126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding.
  • The purpose of this article is to review the available evidence regarding how to safely manage direct-acting oral anticoagulant (DOAC) therapy in patients requiring dental procedures with low-to-moderate risk of bleeding.
  • Articles were eligible for inclusion if the participants were taking DOAC therapy surrounding a dental procedure known to have low-to-moderate risk of bleeding.
  • Variation in the management of DOAC therapy surrounding these procedures was found.
  • Among patients undergoing low-to-moderate risk dental procedures while receiving DOAC therapy, bleeding rates were low regardless of whether the DOAC was held or continued surrounding the procedure.
  • Documented bleeding was mild and easily controlled by local hemostatic measures.
  • Patients can safely continue DOAC therapy surrounding these dental procedures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28506106.001).
  • [ISSN] 1531-1937
  • [Journal-full-title] Journal of pharmacy practice
  • [ISO-abbreviation] J Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; anticoagulation / cardiology / direct-acting oral anticoagulant / medication safety
  •  go-up   go-down


30. Macià I Garau M: Radiobiology of stereotactic body radiation therapy (SBRT). Rep Pract Oncol Radiother; 2017 Mar-Apr;22(2):86-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiobiology of stereotactic body radiation therapy (SBRT).
  • Stereotactic body radiotherapy delivers high doses of radiation to small and well-defined targets in an extreme hypofractionated (and accelerated) scheme with a very high biological effectiveness obtaining very good initial clinical results in terms of local tumor control and acceptable rate of late complications.
  • Only through a better understanding of how high doses of ionizing radiation act, clinicians will know exactly what we do, allowing us in the future to refine our treatments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 2012 Mar;177(3):311-27 [22229487.001]
  • [Cites] Semin Radiat Oncol. 2015 Jan;25(1):54-64 [25481267.001]
  • [Cites] Radiother Oncol. 1999 Dec;53(3):219-26 [10660202.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3381-4 [19661360.001]
  • [Cites] J Appl Clin Med Phys. 2011 Feb 08;12(2):3368 [21587185.001]
  • [Cites] Radiat Oncol. 2008 Oct 31;3:36 [18976463.001]
  • [Cites] Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):446-53 [26696785.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1761-9 [7153088.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):323-7 [20832663.001]
  • [Cites] Radiother Oncol. 2014 Mar;110(3):499-504 [24630539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1043-8 [18755555.001]
  • [Cites] JAMA. 2010 Mar 17;303(11):1070-6 [20233825.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):437-47 [15170446.001]
  • [Cites] Acta Oncol. 1988;27(2):131-46 [3390344.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1026-32 [15519771.001]
  • [Cites] Sci Transl Med. 2015 Mar 11;7(278):278ra34 [25761890.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] J Thorac Oncol. 2009 Aug;4(8):976-82 [19633473.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):11-3 [25835617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):242-9 [15093921.001]
  • [Cites] Future Oncol. 2014 Dec;10(15):2319-28 [25525842.001]
  • [Cites] Sci Transl Med. 2012 Jun 6;4(137):137ra74 [22674552.001]
  • [Cites] Acta Oncol. 2006;45(7):831-7 [16982547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):344-50 [25636759.001]
  • [Cites] Lancet Oncol. 2009 Jul;10(7):718-26 [19573801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):254-62 [24411596.001]
  • [Cites] Cancer Lett. 2015 Jan 1;356(1):82-90 [24125863.001]
  • [Cites] Radiology. 1972 Oct;105(1):135-42 [4506641.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1579-84 [19255320.001]
  • [Cites] Radiother Oncol. 2009 Dec;93(3):408-13 [19454366.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70 [14967443.001]
  • [Cites] Phys Med Biol. 2006 Jun 7;51(11):2813-23 [16723768.001]
  • [Cites] Front Oncol. 2012 Aug 07;2:88 [22891162.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):324-5 [18474308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):336-42 [23433800.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):751-9 [3350731.001]
  • [Cites] Cancer. 2011 Sep 1;117(17):4060-9 [21432842.001]
  • [Cites] Cell. 2011 Mar 4;144(5):646-74 [21376230.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):677-82 [19251380.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1980 Apr;37(4):469-71 [6968732.001]
  • [Cites] J Radiat Res. 2016 Aug;57 Suppl 1:i76-i82 [27006380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):147-53 [18990511.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):549-62 [7558943.001]
  • [Cites] Radiat Res. 2000 Mar;153(3):295-304 [10669551.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):89-91 [16098459.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):847-52 [18262098.001]
  • [Cites] Pract Radiat Oncol. 2012 Oct-Dec;2(4):288-95 [24674167.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1585-91 [19255313.001]
  • [Cites] Br J Radiol. 1953 May;26(305):234-41 [13042090.001]
  • [Cites] Annu Rev Immunol. 2013;31:51-72 [23157435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):757-64 [26530743.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4833-9 [17050868.001]
  • [Cites] Radiother Oncol. 2009 Jun;91(3):360-8 [19410314.001]
  • [Cites] Semin Radiat Oncol. 2008 Oct;18(4):240-3 [18725110.001]
  • [Cites] Ann Surg Oncol. 2011 Apr;18(4):1081-7 [21046264.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):164-70 [11134209.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1159-60 [23517805.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1572-8 [19255321.001]
  • [Cites] Semin Radiat Oncol. 2008 Oct;18(4):234-9 [18725109.001]
  • [Cites] Semin Radiat Oncol. 2015 Apr;25(2):93-9 [25771413.001]
  • [Cites] Cancer. 2012 Apr 15;118(8):2078-84 [22009495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1047-57 [22284028.001]
  • [Cites] Pract Radiat Oncol. 2015 Sep-Oct;5(5):282-5 [26127008.001]
  • [Cites] Blood. 2009 Jul 16;114(3):589-95 [19349616.001]
  • [Cites] Med Phys. 2010 Aug;37(8):4078-101 [20879569.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):486-93 [20350791.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):117-23 [8365932.001]
  • [Cites] Acta Oncol. 2006;45(7):823-30 [16982546.001]
  • [Cites] J Neurosurg Spine. 2007 Aug;7(2):151-60 [17688054.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1006-11 [23102838.001]
  • [Cites] Radiat Oncol J. 2015 Dec;33(4):265-75 [26756026.001]
  • [Cites] N Engl J Med. 2012 Mar 8;366(10 ):925-31 [22397654.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):478-84 [22386374.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):18-9 [23608235.001]
  • [Cites] Radiother Oncol. 2009 Jun;91(3):307-13 [19321217.001]
  • (PMID = 28490978.001).
  • [ISSN] 1507-1367
  • [Journal-full-title] Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
  • [ISO-abbreviation] Rep Pract Oncol Radiother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Radiobiology / SBRT / Stereotactic body radiation therapy
  •  go-up   go-down


31. Klug TE: Peritonsillar abscess: clinical aspects of microbiology, risk factors, and the association with parapharyngeal abscess. Dan Med J; 2017 Mar;64(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment consists of abscess drainage and antimicrobial therapy.
  • There are three accepted methods of surgical intervension: needle aspiration, incision and drainage (ID), and acute tonsillectomy (á chaud).
  • Internationally, there is a strong trend towards less invasive surgical approach to PTA treatment with avoidance of acute tonsillectomy, needle aspiration instead of ID, and in some cases even antibiotic treatment without surgical drainage.
  •   The trend towards de-escalated surgical intervention and increasing reliance on antibiotic treatment, require studies defining the significant pathogens in PTA in order to determine optimal antibiotic regimens.
  • FN-positive patients displayed significantly higher infection markers (CRP and neutrophil counts) than patients infected with other bacteria (P = 0.01 and P < 0.001, respectively).
  • We found increasing levels (at least two-fold) of anti-FN antibodies in eight of 11 FN-positive (in the tonsillar cultures) PTA patients, which was significantly more frequent compared to none of four FN-negative PTA patients and nine of 47 electively tonsillectomized controls (P = 0.026 and P < 0.001, respectively).
  • Blood cultures obtained during acute tonsillectomy mirrored the bacterial findings in the tonsillar specimens with 22% of patients having bacteremia with FN.
  • Conclusions on causality cannot be drawn from this retrospective study, but the pathophysiology behind the increased risk of PTA in smokers may be related to, previously shown, alterations in the tonsillar, bacterial flora or the local and systemical inflammatory and immunological milieu.
  • This finding suggests that FN is not a subsequent overgrowth phenomenon after abscess development, but that FN can act as pathogen in severe acute tonsillitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28260599.001).
  • [ISSN] 2245-1919
  • [Journal-full-title] Danish medical journal
  • [ISO-abbreviation] Dan Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  •  go-up   go-down


32. Zhou B, Liao Y, Guo Y, Tarner IH, Liao C, Chen S, Kermany MH, Tu H, Zhong S, Chen P: Adoptive Cellular Gene Therapy for the Treatment of Experimental Autoimmune Polychondritis Ear Disease. ORL J Otorhinolaryngol Relat Spec; 2017 May 03;79(3):166-177

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adoptive Cellular Gene Therapy for the Treatment of Experimental Autoimmune Polychondritis Ear Disease.
  • In the past, the clinical therapy for autoimmune diseases, such as autoimmune polychondritis ear disease, was mostly limited to nonspecific immunosuppressive agents, which could lead to variable responses.
  • Currently, gene therapy aims at achieving higher specificity and less adverse effects.
  • However, IL-12p40-transduced T cells suppressed IFN-γ and augmented IL-4 production, indicating their potential to act therapeutically by interrupting Th1-mediated inflammatory responses via augmenting Th2 responses.
  • These results indicate that the local delivery of IL-12p40 by T cells could inhibit CIAPED by suppressing autoimmune responses at the site of inflammation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28463837.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Adoptive cellular gene therapy / Autoimmune polychondritis ear disease / IL-12p40
  •  go-up   go-down


33. Li M, Wu H, Wang Y, Yin T, Gregersen H, Zhang X, Liao X, Wang G: Immobilization of heparin/poly-l-lysine microspheres on medical grade high nitrogen nickel-free austenitic stainless steel surface to improve the biocompatibility and suppress thrombosis. Mater Sci Eng C Mater Biol Appl; 2017 Apr 01;73:198-205

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Thrombosis formation, restenosis, and delayed endothelium regeneration continue to be a challenge for coronary artery stent therapy.
  • Furthermore, for plasma coagulation tests, the activated partial thromboplastin time and thrombin time were prolonged and depended on the heparinfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier B.V. All rights reserved.
  • (PMID = 28183598.001).
  • [ISSN] 1873-0191
  • [Journal-full-title] Materials science & engineering. C, Materials for biological applications
  • [ISO-abbreviation] Mater Sci Eng C Mater Biol Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Blood compatibility / Coronary stent / Heparin / High nitrogen nickel-free austenitic stainless steel / Microsphere
  •  go-up   go-down


34. Guerra ES, Lee CK, Specht CA, Yadav B, Huang H, Akalin A, Huh JR, Mueller C, Levitz SM: Central Role of IL-23 and IL-17 Producing Eosinophils as Immunomodulatory Effector Cells in Acute Pulmonary Aspergillosis and Allergic Asthma. PLoS Pathog; 2017 Jan;13(1):e1006175

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By in vivo intracellular cytokine staining and confocal microscopy, we observed that eosinophils act as local sources of IL-23 and IL-17.
  • Given the postulated role for IL-17 in asthma pathogenesis, we assessed whether eosinophils could act as sources of IL-23 and IL-17 in models where mice were sensitized to either A. fumigatus antigens or ovalbumin (OVA).
  • These data establish a new paradigm in acute and allergic aspergillosis whereby eosinophils act not only as effector cells but also as immunomodulatory cells driving the IL-23/IL-17 axis and contributing to inflammatory cell recruitment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 2015 Jun;135(6):1643-1643.e3 [25649077.001]
  • [Cites] Respirology. 2006 Jan;11(1):54-61 [16423202.001]
  • [Cites] J Allergy Clin Immunol. 2012 Sep;130(3):572-84 [22935586.001]
  • [Cites] Med Mycol. 2013 May;51(4):361-70 [23210682.001]
  • [Cites] Eur Respir J. 2006 Mar;27(3):615-26 [16507864.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1218-22 [16670765.001]
  • [Cites] Clin Exp Allergy. 2014 Sep;44(9):1119-36 [24961290.001]
  • [Cites] Biochim Biophys Acta. 2011 Nov;1810(11):1066-79 [21315804.001]
  • [Cites] J Allergy Clin Immunol. 2001 Sep;108(3):430-8 [11544464.001]
  • [Cites] Periodontol 2000. 2015 Oct;69(1):142-59 [26252407.001]
  • [Cites] Clin Microbiol Rev. 2009 Oct;22(4):535-51 [19822887.001]
  • [Cites] PLoS One. 2013;8(2):e56651 [23441211.001]
  • [Cites] PLoS Pathog. 2015 Mar 12;11(3):e1004701 [25764512.001]
  • [Cites] Nat Rev Microbiol. 2003 Oct;1(1):17-24 [15040176.001]
  • [Cites] Nat Rev Immunol. 2010 Jul;10(7):479-89 [20559326.001]
  • [Cites] J Infect Dis. 1986 Sep;154(3):483-9 [3525696.001]
  • [Cites] J Immunol. 2009 Apr 15;182(8):4938-46 [19342673.001]
  • [Cites] PLoS One. 2011;6(10):e26232 [22039448.001]
  • [Cites] Immunol Cell Biol. 2010 Mar-Apr;88(3):250-6 [20065995.001]
  • [Cites] Nat Immunol. 2014 Feb;15(2):143-51 [24362892.001]
  • [Cites] PLoS Pathog. 2013;9(12):e1003743 [24348239.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Mar;52(3):1176-8 [18160526.001]
  • [Cites] Nat Rev Immunol. 2005 Dec;5(12):953-64 [16322748.001]
  • [Cites] J Exp Med. 2011 Jan 17;208(1):167-80 [21187318.001]
  • [Cites] Eukaryot Cell. 2015 Nov;14(11):1073-80 [26318395.001]
  • [Cites] Appl Microbiol Biotechnol. 2012 Jan;93(2):467-72 [22094977.001]
  • [Cites] Infect Immun. 2014 Aug;82(8):3199-205 [24842927.001]
  • [Cites] Lancet Infect Dis. 2011 Oct;11(10):780-92 [21958581.001]
  • [Cites] Mol Ther. 2010 Mar;18(3):511-8 [19935781.001]
  • [Cites] Immunity. 2015 Nov 17;43(5):845-58 [26588778.001]
  • [Cites] PLoS One. 2014 Jun 10;9(6):e98502 [24914809.001]
  • [Cites] PLoS Pathog. 2015 Jan 26;11(1):e1004589 [25621893.001]
  • [Cites] Cell Rep. 2012 Dec 27;2(6):1762-73 [23200858.001]
  • [Cites] Clin Dev Immunol. 2013;2013:968549 [23956763.001]
  • [Cites] J Immunol Methods. 2007 Oct 31;327(1-2):63-74 [17716680.001]
  • [Cites] Immunity. 2011 Feb 25;34(2):149-62 [21349428.001]
  • [Cites] Dis Model Mech. 2008 Nov-Dec;1(4-5):213-20 [19093027.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):681-5 [16785881.001]
  • [Cites] Mucosal Immunol. 2015 May;8(3):464-75 [25807184.001]
  • [Cites] J Exp Med. 2016 Apr 4;213(4):555-67 [26951334.001]
  • [Cites] Cell Host Microbe. 2011 May 19;9(5):415-24 [21575912.001]
  • [Cites] PLoS Pathog. 2014 Feb 20;10(2):e1003940 [24586155.001]
  • [Cites] Biochem Biophys Res Commun. 2014 Oct 10;453(1):1-6 [25204502.001]
  • [Cites] Nat Med. 2015 Jul;21(7):719-29 [26121196.001]
  • [Cites] Blood. 1981 Jun;57(6):1099-104 [7225570.001]
  • [Cites] J Allergy Clin Immunol. 2012 Feb;129(2):280-91; quiz 292-3 [22284927.001]
  • [Cites] Allergy Rhinol (Providence). 2012 Fall;3(2):e50-4 [23342289.001]
  • [Cites] Infect Immun. 2012 Apr;80(4):1424-36 [22252873.001]
  • [Cites] Ann Allergy Asthma Immunol. 2014 Jul;113(1):3-8 [24795292.001]
  • [Cites] Infect Immun. 2014 Mar;82(3):1315-25 [24379296.001]
  • [Cites] Med Mycol. 2009;47 Suppl 1:S261-70 [18654921.001]
  • [Cites] PLoS Pathog. 2015 Feb 06;11(2):e1004643 [25659141.001]
  • [Cites] Nat Rev Immunol. 2013 Jan;13(1):9-22 [23154224.001]
  • [Cites] Am J Respir Crit Care Med. 2014 Nov 15;190(10):1094-101 [25162311.001]
  • [Cites] Sci Transl Med. 2012 Dec 19;4(165):165rv13 [23253612.001]
  • [Cites] Am J Rhinol Allergy. 2014 Mar-Apr;28(2):103-9 [24717945.001]
  • [Cites] Cytometry A. 2004 Oct;61(2):170-77 [15382026.001]
  • [Cites] J Clin Invest. 2016 Sep 1;126(9):3279-95 [27548519.001]
  • [Cites] Nat Immunol. 2015 Jan;16(1):45-56 [25521684.001]
  • [Cites] Clin Med Insights Circ Respir Pulm Med. 2011;5:37-47 [21912491.001]
  • [Cites] J Immunol. 2010 Jun 1;184(11):6350-8 [20483787.001]
  • [Cites] MBio. 2015 Dec 22;6(6):e01905-15 [26695631.001]
  • [Cites] PLoS Pathog. 2014 Sep 25;10(9):e1004378 [25255025.001]
  • [Cites] J Immunol. 2008 Nov 1;181(9):6117-24 [18941201.001]
  • [Cites] Nat Rev Immunol. 2014 Sep;14(9):585-600 [25145755.001]
  • [Cites] Curr Opin Pulm Med. 2016 Jan;22(1):3-9 [26574717.001]
  • [Cites] J Immunol. 2008 Sep 15;181(6):4004-9 [18768855.001]
  • [Cites] Clin Microbiol Rev. 1999 Apr;12(2):310-50 [10194462.001]
  • (PMID = 28095479.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI095213
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. d'Elbée M, Baumevieille M, Dumartin C: [Cooperation according to French Law "hospital, patients, health and territories": Pharmacists' involvement in Aquitaine region]. Rev Epidemiol Sante Publique; 2017 Jun;65(3):231-239

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Missions de coopération introduites par la loi « hôpital, patients, santé et territoires » : participation des pharmaciens d’officine en Aquitaine.
  • BACKGROUND: In 2009, the French Act "Hospital, Patients, Health and Territories" (loi "Hôpital, Patients, Santé et Territoires") reorganized the outpatient care pathway and defined missions aimed at improving cooperation between pharmaceutical and medical professionals.
  • METHODS: In partnership with the local health authorities "Agence régionale de santé", we conducted a survey via an online questionnaire sent to pharmacy holders in July 2014 in Aquitaine region.
  • Regarding collaborative activities, the majority of pharmacists (78%) had conducted interviews with their patients taking vitamin K antagonist therapy and they were willing to continue (87%).
  • The main obstacles for engaging in these activities were the lack of time, lack of knowledge about these missions and the lack of remuneration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Masson SAS. All rights reserved.
  • (PMID = 28262371.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'epidemiologie et de sante publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Keywords] NOTNLM ; Enquête sur les services de santé / Health care survey / Parcours de soins coordonnés / Partnership practice / Pharmacies / Pharmacist / Public health / Santé publique
  •  go-up   go-down


36. Cheng KJ, Wang SQ, Xu YY: Different roles of <i>Staphylococcus aureus</i> enterotoxin in different subtypes of nasal polyps. Exp Ther Med; 2017 Jan;13(1):321-326

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different roles of <i>Staphylococcus aureus</i> enterotoxin in different subtypes of nasal polyps.
  • This study was designed to investigate the role of inflammation and <i>Staphylococcus aureus</i> enterotoxin (SE) in this disease.
  • The supernatant ECP and MPO levels were elevated in the CRSwNP group compared with the control group, but no significant difference in the serum total IgE and ECP levels were observed between the CRSwNP and control groups.
  • In addition, the non-eosinophilic and eosinophilic CRSwNP groups showed significant elevations in supernatant total IgE, SEA and SEB levels compared with the control group.
  • Additionally, local indicators reflect the inflammatory status more accurately than do serum indicators.
  • SEs may act as an infection factor rather than as a superantigen in Chinese non-eosinophilic CRSwNP patients.
  • Thus, long-term antibiotic therapy may be an option for Chinese non-eosinophilic CRSwNP patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28123509.001).
  • [ISSN] 1792-0981
  • [Journal-full-title] Experimental and therapeutic medicine
  • [ISO-abbreviation] Exp Ther Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Keywords] NOTNLM ; Staphylococcus aureus enterotoxin / chronic rhinosinusitis with nasal polyps / eosinophil cationic protein / myeloperoxidase / superantigen
  •  go-up   go-down


37. Yu B, Ma Z, Guan C, Liu G, Ding H, Yin Y, Han W, Taimei Baofa Cancer Hospital: Clinical introtumoral chemoimmunotherapy for late stages of lung cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e21001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21001 Background: Currently cancer therapy is not satisfied with the effectiveness of available treatment.
  • Therefore, it resulted in one year survial rate is 36%(treated) compared 14%(control) with P<0.05.in addition to the innovation for sustained drug release, more importantly, ChemoVac provides a new option for cancer treatment by integrating local chemotherapeutic effect with systemic anti-tumor immunity; cell death induced by chemotherapeutic drugs is a priming event and allows the injected tumor act as its own vaccine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022345.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Kwiatt M, Spitz FR, LaCouture TA: Early experience with robotic radiosurgery for local control of liver metastasis. J Clin Oncol; 2012 Feb;30(4_suppl):295

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early experience with robotic radiosurgery for local control of liver metastasis.
  • : 295 Background: Liver toxicity limits radiation therapy for liver metastasis; however, robotic radiosurgery delivers effective doses with limited toxicities.
  • Preradiosurgery and follow-up abdominal computed tomography (CT) scans reviewed for treatment response.
  • Our primary endpoint was local recurrence, defined as increased enhancement or tumor progression within the treatment field on follow-up CT scan.
  • Prior to radiosurgery 27 of 33 patients (81.8%) had undergone surgical resection of primary tumor, 26 of 33 patients (78.8%) were treated with chemotherapy for metastatic disease, and 15 of 33 patients (45.5%) had non-liver radiation therapy.
  • Median time from primary diagnosis to radiosurgery treatment was 33.3 months (5.7 to 320 months).
  • Sixteen patients had disease progression outside the treatment field (15 liver, 6 systemic) with a median time to progression of 4.6 months (0.9 to 17.6).
  • Five lesions (13.5%) had in field progression with a median time to progression of 10 months (2.6 to 13.1).
  • CONCLUSIONS: Robotic radiosurgery offers a potential local therapy for patients with metastatic liver disease with limited toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27982843.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Haddad RI, Gokhale AS, Wirth L, Weeks L, Faucher J, Hallar M, Cavacini LA, Posner MR: Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). J Clin Oncol; 2004 Jul 15;22(14_suppl):9716

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These cytokines act through pro-angiogenic and mitogenic effects.
  • Active co-morbid illnesses, addictions, use of steroids or NSAIDS, or active anticancer therapy immediately prior to sampling were exclusion criteria.
  • 7/7 NV and 4/5 NED had levels < 20 pg/ml (mean of 13 and 15, respectively).
  • In the RD group, 12/15 with metastatic disease (MD) and 4/5 with local regional recurrence (LRR) had IL-8 levels of > 20 (mean 44 and 29, respectively).
  • It is possible that serum IL-8 can be used as a prognostic test in patients with ND or at risk for recurrence.
  • IL-8 may also be a potential therapeutic target to control tumor growth and metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016407.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Bardia A, Blackford AL, Lin J, Armstrong AJ, King S, Rudek MA, Yegnasubramanian ST, Carducci MA: A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). J Clin Oncol; 2013 Feb 20;31(6_suppl):219

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: To determine if D leads to demethylation changes [i.e. decreased global 5<sup>me</sup>C DNA content from peripheral blood mononuclear cells (PBMC)] we conducted an open-label, dose escalation trial of D in men with non-metastatic recurrent PCa after local therapy.
  • >10% decrease in global 5<sup>me</sup>C content) in <3 patients was observed in cohort 1.
  • Secondary endpoints included rate of PSA progression at 6 months (i.e. confirmed >50% rise over baseline and >2 ng/mL above nadir), changes in PSA doubling time (PSADT) and safety/tolerability.
  • Cohort 2 accrued a total of 10 patients, 3 (30.0%) of which had >10% decrease in global 5<sup>me</sup>C content.
  • CONCLUSIONS: A minority of patients had global PBMC demethylation changes, consistent with D acting as a probable demethylating agent in those individuals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28137035.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Kanda S, Narita S, Komine N, Kitajima S, Yamauchi M, Sugita A, Saito Y, Habuchi T: [A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy]. Hinyokika Kiyo; 2016 Dec;62(12):647-650
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy].
  • We present a case of gigantic prostate tumor in a patient with castration-resistant prostate cancer with successful local control by external-beam radiation therapy.
  • He achieved a PSA nadir at 4 months after the initial androgen deprivation therapy and was diagnosed with castration-resistant prostate cancer three years later.
  • Abdominal computed tomography scan showed a gigantic prostatic mass occupying the whole pelvic cavity along with multiple lymph node, bone and liver metastases.
  • He underwent external beam radiation therapy (60 Gy) to the prostate, which brought about excellent local control with a 96.7% shrinkage of tumor at 2 months after radiation therapy.
  • [MeSH-minor] Aged. Biopsy, Needle. Humans. Male. Proton Therapy. Tomography, X-Ray Computed. Treatment Outcome. Urinary Retention / etiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28103659.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Schulzeck S, Wulf H: [Local therapy with capsaicin or ASS in chronic pain]. Schmerz; 1997 Oct 24;11(5):345-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local therapy with capsaicin or ASS in chronic pain].
  • OBJECTIVE: To provide a brief review of the current state of topical treatment with capsaicin or acetylsalicylic acid (ASA) for therapy of chronic pain syndromes.
  • Because of its effects, it is obvious to try for the therapy of circumscribed neuropathic pain.
  • Capsaicin acts by depleting stores of substance P and other neurotransmitters, resulting in a blockade of a specific group of sensory afferents.
  • Therefore, and because clinical efficacy and advantages over other therapies have not been demonstrated up to now, capsaicin cannot be classified as standard therapy.
  • Therefore, topical ASA therapy for (post)herpetic neuralgia is mainly based on a few enthusiastic case reports rather than on well founded investigations.
  • Furthermore, the discrimination of local from systemic effects, the toxicological profile of longterm topical treatment, and the mechanism of action has not been evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12799806.001).
  • [ISSN] 0932-433X
  • [Journal-full-title] Schmerz (Berlin, Germany)
  • [ISO-abbreviation] Schmerz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Antoniu SA: Inhaled corticosteroids in COPD: systemic effects of a local therapy? Expert Opin Pharmacother; 2008 Dec;9(18):3271-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhaled corticosteroids in COPD: systemic effects of a local therapy?
  • OBJECTIVE: Evaluation of the systemic anti-inflammatory effects of inhaled corticosteroids alone or in combination with long acting beta2-agonists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Respir Crit Care Med. 2008 Jun 1;177(11):1207-14 [18310480.001]
  • (PMID = 19040347.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Sudanese A, Avella M, Toni A, Boriani S, Baldini N, Monesi M, Battistini A, Mancini A, Campanacci M: [Therapy of non-metastatic Ewing's sarcoma (pelvis excluded). Results obtained in 48 cases combining local therapy (radiation and/or surgical) and adjuvant chemotherapy with vincristine, adriamycin, dactinomycin and cyclophosphamide]. Minerva Med; 1987 Apr 15;78(7):473-82
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of non-metastatic Ewing's sarcoma (pelvis excluded). Results obtained in 48 cases combining local therapy (radiation and/or surgical) and adjuvant chemotherapy with vincristine, adriamycin, dactinomycin and cyclophosphamide].
  • [Transliterated title] Terapia del sarcoma di Ewing non metastatico (pelvi esclusa). Risultati ottenuti in 48 casi associando alla terapia locale (radiante e/o chirurgica) una chemioterapia adiuvante con vincristina, adriamicina, dactinomicina e ciclofosfamide.
  • Combined therapy was used on a consecutive series of 48 patients with extrapelvic Ewing's sarcoma at the Rizzoli Orthopaedic Institute.
  • The adjuvant chemotherapy protocol (VCR, ADM, D-ACT, EDX) was identical in all patients whereas local treatment consisted of amputation, resection and radiation treatment or radiation alone.
  • As far as the type of local treatment is concerned, the percentage of local recurrences and metastases was lower when the primary lesion was treated with surgery or surgery combined with radiotherapy, rather than radiation treatment alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Neoplasm Metastasis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 3574734.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


45. deVere White R: Nonsurgical management of patients with stage D1 adenocarcinoma of prostate: risks vs benefits. Urology; 1984 Nov;24(5 Suppl):12-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Any purely local therapy (e.g., radical prostatectomy) appears to offer little in terms of the risk:benefit ratio.
  • However, some form of local therapy is appropriate, since the untreated primary may continue to act as a source of metastases.
  • 125I implantation with concomitant systemic therapy is an excellent therapeutic option for the majority of these patients.
  • If one accepts the premise that local therapy is of limited value in metastatic disease, systemic treatment at the time of initial diagnosis should be considered.
  • According to the data presented by the Mayo Clinic Group, immediate orchiectomy may be the best form of therapy.
  • An alternative to orchiectomy is estrogen therapy or the more recently introduced GnRH analogues.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 6541825.001).
  • [ISSN] 0090-4295
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


46. Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F: Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas; 2005 Feb 14;50(2):98-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
  • BACKGROUND: When genital atrophy exists, systemic hormone therapy (HT) has a timing until to induce vaginal proliferation and symptomatic relieve.
  • Thus, in order to obtain a prompt improvement, the association of local therapy acting on the genital epithelium to the systemic treatment should be considered.
  • OBJECTIVE: To evaluate the effects of a combined therapy consisting of vaginal estriol with transdermal 17-beta-estradiol (50 microg/day) plus medroxyprogesterone acetate (5 mg/day) per os in shortening the period of uro-genital symptoms.
  • Patients use the local medication daily for the first 3 weeks and twice-weekly thereafter.
  • In the first visit, electible patients after written informed consent were randomized to receive HT plus local estriol or placebo.
  • All the subjects had baseline studies, including medical history, physical examination, blood and urine analysis.
  • In order to evaluate the effect of local treatment on urinary and genital symptoms, a score for genital, urinary and colposcopic complaints (0 minimum-100 maximum) was developed.
  • This score and Blatt-Kuperman were recorded and performed in every control.
  • Additionally, the improvement in urinary symptoms at the end of the study was similar for both groups (from 16.5 +/- 6.1 to 8.5 +/- 2.4 for E group and from 15.8 +/- 7.8 to 8.8 +/- 2.7 for P group; P < 0.01 versus basal); however, those women in group E reached significant improvement on urinary complaints since the first month of treatment.
  • [MeSH-major] Estriol / therapeutic use. Postmenopause / physiology. Urologic Diseases / drug therapy. Vagina / pathology. Vaginal Diseases / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Administration, Intravaginal. Adult. Atrophy / drug therapy. Colposcopy. Contraceptive Agents, Female / therapeutic use. Dose-Response Relationship, Drug. Estradiol / therapeutic use. Estrogen Replacement Therapy. Female. Humans. Medroxyprogesterone Acetate / therapeutic use. Middle Aged. Papanicolaou Test. Treatment Outcome. Vaginal Creams, Foams, and Jellies. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Diseases.
  • Hazardous Substances Data Bank. ESTRIOL .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653006.001).
  • [ISSN] 0378-5122
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 0 / Vaginal Creams, Foams, and Jellies; 4TI98Z838E / Estradiol; C2QI4IOI2G / Medroxyprogesterone Acetate; FB33469R8E / Estriol
  •  go-up   go-down


47. Cheng L, Hostetler KY, Gardner MF, Avila CP Jr, Bergeron-Lynn G, Severson GM, Freeman WR: Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA). Curr Eye Res; 1999 Mar;18(3):161-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The retinal level of the drug was 292 microM at day one, 75 microM at the fifth week and 32 microM at the tenth week, which was still more than ten times higher than the IC90 against HCMV.
  • Intravitreal liposomal ODG-PFA may be expected to be a long acting potent local therapy for CMV retinitis.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Foscarnet .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10342370.001).
  • [ISSN] 0271-3683
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY 11832; United States / NEI NIH HHS / EY / EYO 7366
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / 1-O-octadecyl-sn-glycerol-3-phosphonoformate; 0 / Antiviral Agents; 0 / Drug Carriers; 0 / Liposomes; 0 / Phospholipid Ethers; 0 / Prodrugs; 364P9RVW4X / Foscarnet
  •  go-up   go-down


48. Sealy PI, Nguyen C, Tucci M, Benghuzzi H, Cleary JD: Delivery of antifungal agents using bioactive and nonbioactive bone cements. Ann Pharmacother; 2009 Oct;43(10):1606-15
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antifungal-impregnated cement is sometimes used as adjunctive therapy.
  • Ceramic nonabsorbable impregnated devices must be removed after their lifespan expires and may necessitate another surgical procedure that can increase surgical risk and cost.
  • However, there have been no controlled trials demonstrating improved therapeutic outcomes with local therapy and assessing whether biodegradable materials act as a new focus for infection.
  • [MeSH-minor] Animals. Calcium / blood. Calcium / metabolism. Calcium Phosphates / chemistry. Cattle. Cells, Cultured. Delayed-Action Preparations. Humans. Hydroxyapatites / chemistry. In Vitro Techniques. Osteoblasts / drug effects. Osteoblasts / metabolism. Osteomyelitis / drug therapy. Osteomyelitis / microbiology. Polymethyl Methacrylate / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755620.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Biocompatible Materials; 0 / Bone Cements; 0 / Calcium Phosphates; 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / Hydroxyapatites; 0 / beta-tricalcium phosphate; 0 / hydroxyapatite cement; 9011-14-7 / Polymethyl Methacrylate; SY7Q814VUP / Calcium
  •  go-up   go-down


49. Etienne J, Dorme N, Bourg-Heckly G, Raimbert P, Fékété F: [Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer]. Bull Acad Natl Med; 2000;184(8):1731-44; discussion 1744-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer].
  • [Transliterated title] Traitement curatif local des adénocarcinomes superficiels sur endobrachyoesophage. Premiers résultats de thérapie photodynamique avec un nouveau photosensibilisateur.
  • Pre-cancerous lesions and mucosally confined superficial cancers can benefit from local therapy given with curative intent due to the absence of near metastatic lymph nodes.
  • Photodynamic therapy (PDT) which acts by laser irradiation with an appropriate wave-length after administration of a photosensitiser retained preferentially by the cancerous tissue can destroy tumour cells selectively, but its efficiency depends upon the photosensitiser.
  • Irradiation time was 12,5 mn.
  • Temoporfin has contributed notably to the field of photodynamic therapy compared to previously used sensitisers.
  • Subject to validation of the method on a greater number of patients, the first results obtained on superficial cancer in Barrett's aesophagus allow us to propose green light Temoporfin PDT as an alternative first line therapy with curative intent.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / therapy. Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Esophageal Neoplasms / therapy. Mesoporphyrins / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Precancerous Conditions / etiology. Precancerous Conditions / therapy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11471391.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


50. Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF: Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol; 2003 Feb;14(2):227-32
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study was to evaluate the impact of a dose-dense primary chemotherapy on pathological response rate (pCR) in patients with locally advanced breast cancer (LABC) treated with combined modality therapy.
  • PATIENTS AND METHODS: Stage IIIA/IIIB patients received three courses of induction chemotherapy (ICT) with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by local therapy (total mastectomy or segmental mastectomy with axillary nodes dissection) and adjuvant chemotherapy (ACT) with three courses of CEF alternated with three courses of cyclophosphamide, methotrexate, 5-fluorouracil (CMF).
  • Patients were randomized to receive ICT and ACT every 3 weeks (arm A, 'standard treatment') or every 2 weeks with granulocyte-macrophage colony-stimulating factor (GM-CSF) support (arm B, 'dose-dense treatment').
  • Median duration of treatment (ICT+local+ACT) was 183 days (range 0-265) in arm A and 139 days (0-226) in arm B.
  • Median overall survival was 7.8 years in standard therapy: this figure has not yet been reached in the dose-dense treatment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12562649.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 3Z8479ZZ5X / Epirubicin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


51. Urushizaki I: [Palliative therapy in cancer. 6. Quality of life and BRM therapy in cancer-patients]. Gan To Kagaku Ryoho; 1990 Oct;17(10):2119-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Palliative therapy in cancer. 6. Quality of life and BRM therapy in cancer-patients].
  • In recent years, various fields of cancer therapy have seen the development and application of treatment modalities which take into account the quality of the patients.
  • Systemic administration of exogenous cytokines to act against a tumor at a distant site may not be as successful as more localized therapy in situation.
  • In most circumstances, cytokines are produced transiently at a local site acting in an autocrine or paracrine manner.
  • So, the local injections of TNF and LAK cells are effective to decrease tumor size without the side effects.
  • [MeSH-major] Immunologic Factors / therapeutic use. Neoplasms / therapy. Palliative Care. Quality of Life
  • [MeSH-minor] Combined Modality Therapy. Cytokines / blood. Cytokines / therapeutic use. Humans. Immunotherapy, Adoptive

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 1699499.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunologic Factors
  • [Number-of-references] 29
  •  go-up   go-down


52. Oden ZM, Selvitelli DM, Bouxsein ML: Effect of local density changes on the failure load of the proximal femur. J Orthop Res; 1999 Sep;17(5):661-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of local density changes on the failure load of the proximal femur.
  • Presently, all therapies approved for treatment and prevention of osteoporosis involve pharmacological agents that act systemically.
  • In this study, we evaluated the feasibility of preventing osteoporotic hip fractures with local, rather than systemic, therapy.
  • Our hypothesis is that local therapy to increase bone density may be as effective as systemic therapy in reducing fracture risk.
  • Thus, the goal of this investigation was to use finite element analyses to study the effect of a localized increase in bone density on the strength of an osteopenic, human femur.

  • MedlinePlus Health Information. consumer health - Hip Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Orthop Res. 2000 Mar;18(2):337 [10815838.001]
  • (PMID = 10569474.001).
  • [ISSN] 0736-0266
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


53. Vokes EE, Panje WR, Weichselbaum RR, Schilsky RL, Moran WJ, Awan AM, Guarnieri CM: Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg; 1988 Apr;98(4):295-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
  • Both drugs are effective single agents, have shown synergistic activity in vitro, and can act as radiation sensitizers.
  • Sixteen patients have completed their therapy.
  • Eleven patients had recurrent disease after previous therapy with surgery (11 patients), radiotherapy (9 patients), and combination chemotherapy (4 patients).
  • Five patients had not received previous local therapy.
  • Of 15 patients evaluable for response, 9 had complete response, including 5 patients who had earlier local therapy; 5 had partial response; and 1 failed to respond.
  • This regimen has shown impressive activity in a cohort of patients who are not usually responsive to other types of currently available therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Hydroxyurea / administration & dosage. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, High-Energy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 3132681.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] U3P01618RT / Fluorouracil; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


54. Babiĭ IaS, Bezhenar AA, Gladkiĭ AV: [Lung study in bronchial asthma using x-ray pneumopolygraphy]. Vrach Delo; 1989 Jan;(1):69-70
MedlinePlus Health Information. consumer health - Asthma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Roentgenpneumopolygraphy (RPPG) was used to examine 48 patients with bronchial asthma and all patients showed a reduction of one or several indices of zonal ventilation and/or biomechanics of the respiratory act.
  • But most patients revealed local disorders of ventilation resistant to the effect of broncholytic agents.
  • Local therapy of the corresponding lung regions produced a positive effect.

  • Genetic Alliance. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 2718453.001).
  • [ISSN] 0049-6804
  • [Journal-full-title] Vrachebnoe delo
  • [ISO-abbreviation] Vrach Delo
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] USSR
  • [Chemical-registry-number] 0 / Bronchodilator Agents
  •  go-up   go-down


55. Hill JS, Kahl SB, Stylli SS, Nakamura Y, Koo MS, Kaye AH: Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. Proc Natl Acad Sci U S A; 1995 Dec 19;92(26):12126-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer.
  • The median survival for primary tumors is < 12 months, with most recurring at the site of the original tumor, indicating that a more aggressive local therapy is required to eradicate the unresectable "nests" of tumor cells invading into adjacent brain.
  • Two adjuvant therapies with the potential to destroy these cells are porphyrin-sensitized photodynamic therapy (PDT) and boron-sensitized boron neutron capture therapy (BNCT).
  • The ability of a boronated porphyrin, 2,4-(alpha, beta-dihydroxyethyl) deuteroporphyrin IX tetrakiscarborane carboxylate ester (BOPP), to act as a photosensitizing agent was investigated in vitro with the C6 rat glioma cell line and in vivo with C6 cells grown as an intracerebral tumor after implantation into Wistar rats.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] N Engl J Med. 1979 Jun 28;300(26):1469-71 [221807.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):917-21 [2932542.001]
  • [Cites] Neurosurgery. 1985 Dec;17(6):883-90 [2934641.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):408-15 [2952899.001]
  • [Cites] Radiat Res. 1987 Jul;111(1):14-25 [3602351.001]
  • [Cites] Br J Cancer. 1987 Jun;55(6):647-9 [3620307.001]
  • [Cites] J Neurosurg. 1987 Dec;67(6):864-73 [3316532.001]
  • [Cites] J Neurosurg. 1987 Dec;67(6):889-94 [3681427.001]
  • [Cites] J Neurosurg. 1988 Jul;69(1):1-14 [3288722.001]
  • [Cites] J Neurosurg. 1989 Feb;70(2):175-82 [2643685.001]
  • [Cites] Photochem Photobiol. 1989 Jul;50(1):45-53 [2527374.001]
  • [Cites] Neurosurgery. 1990 Feb;26(2):248-54 [2137904.001]
  • [Cites] Can J Neurol Sci. 1990 May;17(2):193-8 [2357655.001]
  • [Cites] J Neurooncol. 1992 Jan;12(1):33-46 [1541977.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1785-9 [1542672.001]
  • [Cites] Photochem Photobiol. 1991 Nov;54(5):725-32 [1724698.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] Hum Gene Ther. 1993 Feb;4(1):39-69 [8384892.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Neurosurgery. 1981 Dec;9(6):672-8 [7322332.001]
  • (PMID = 8618857.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 37961
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2,4-(alpha,beta-dihydroxyethyl)deuteroporphyrin IX tetrakiscarborane carboxylate ester; 0 / Boron Compounds; 0 / Deuteroporphyrins; 0 / Photosensitizing Agents; 68335-15-9 / Hematoporphyrin Derivative
  • [Other-IDs] NLM/ PMC40309
  •  go-up   go-down


56. James PP, Mead GM: Sanctuary site relapse in chemotherapy-treated testicular cancer. Ann Oncol; 1992 Jan;3(1):41-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The testis and central nervous system (CNS) may act as sanctuary sites for testicular germ cell tumours, as cytotoxic drugs penetrate these areas less well than systemic sites.
  • Two patients were rendered disease-free; one died of progression of his local disease only.
  • Sanctuary site tumour should be considered when relapse occurs in the setting of otherwise chemosensitive disease; local therapy may be curative.

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 1376616.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


57. Stüttgen G: [Results and consequences of long-term urea therapy for clinical practice]. Hautarzt; 1992;43 Suppl 11:9-12
Hazardous Substances Data Bank. UREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results and consequences of long-term urea therapy for clinical practice].
  • In the development of clinical symptoms of atopic constitutional neurodermatitis, the application of urea can 1. regulate corneal layer lipids by hydrating the corneal layer and influencing transepidermal water loss, 2. reduce itching via inhibition of tryptic enzymes in the skin and, 3. diminish the susceptibility of the skin to infection by directly acting on the cell membranes of bacteria and fungi.
  • In the present study, the combination of urea and hydrocortisone was used for acute attacks and urea ointment for chronic therapy.
  • Urea therapy in the form of a hydrocortisone-urea ointment represents an effective and low-side effect therapy of this type of chronic dermatosis.
  • Local therapy with other corticosteroids was only reported as necessary in 16% of the cases.
  • In addition to its special properties in the therapy of neurodermatitis, urea also ranks high as a physiological substitution.
  • [MeSH-major] Dermatitis, Atopic / drug therapy. Urea / therapeutic use
  • [MeSH-minor] Administration, Topical. Anti-Inflammatory Agents / administration & dosage. Drug Combinations. Humans. Hydrocortisone. Ointments. Pruritus / drug therapy. Water Loss, Insensible / drug effects

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 1555945.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Drug Combinations; 0 / Ointments; 8W8T17847W / Urea; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


58. Prieur AM: [Drug therapy of inflammatory arthritis in children]. Rev Prat; 1994 Dec 1;44(19):2593-9
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug therapy of inflammatory arthritis in children].
  • [Transliterated title] Traitements médicamenteux des arthrites inflammatoires de l'enfant.
  • Slow acting antirheumatic drugs are mostly used in the polyarticular subtype.
  • Oligoarticular subtype, the long term prognosis of which is fair, is a good indication to local therapy.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Adrenal Cortex Hormones / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Arthritis / drug therapy. Arthritis, Juvenile / drug therapy

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 7855528.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


59. Frommelt L: Principles of systemic antimicrobial therapy in foreign material associated infection in bone tissue, with special focus on periprosthetic infection. Injury; 2006 May;37 Suppl 2:S87-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Principles of systemic antimicrobial therapy in foreign material associated infection in bone tissue, with special focus on periprosthetic infection.
  • Foreign material associated infection in bone tissue is mostly characterized by the features of sessile pathogens acting from the foreign material surface.
  • Therapy is based on surgical revision, with removal of the foreign material and supplementary antimicrobial therapy.
  • Empirical antimicrobial therapy cannot be recommended unless life threatening septicemia occurs.
  • Therefore, antibiotics must be administered in high dosage for an extended period of time.
  • The options of antimicrobial therapy are: 1.
  • 3. Surgical revision with retention of the foreign material and long-term antibiotic therapy including rifampicin: This procedure is possible in early, not yet established foreign material infections.
  • 4. Treatment of the periprosthetic infection: Surgical revision with exchange of the prosthesis combined with systemic (and optional local) therapy, regardless whether the revision is performed in 1 - or multiple-stages.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Bone Diseases, Infectious / drug therapy. Postoperative Complications / drug therapy
  • [MeSH-minor] Device Removal. Humans. Osteomyelitis / drug therapy. Prostheses and Implants / adverse effects. Prosthesis-Related Infections / drug therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bone Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16651077.001).
  • [ISSN] 0020-1383
  • [Journal-full-title] Injury
  • [ISO-abbreviation] Injury
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  •  go-up   go-down


60. Spies CM, Burmester GR, Buttgereit F: Analyses of similarities and differences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis - a systematic comparison. Clin Exp Rheumatol; 2009 Jul-Aug;27(4 Suppl 55):S152-8
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of similarities and differences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis - a systematic comparison.
  • In rheumatoid arthritis (RA), GCs are used systemically at several different dosages and/or local (intraarticular) therapy.
  • In comparison, patients with ankylosing spondylitis (AS) are considered to be less responsive to GC therapy than patients with RA, although controlled studies on the effects of low-dose GCs in AS are lacking.
  • In AS, GCs are mainly used for local therapy and occasionally for systemic pulse therapy only.
  • GCs act on primary and secondary immune cells via different mechanisms of action: cytosolic GC receptor (cGCR)-mediated genomic and non-genomic effects, membrane-bound GC receptor (mGCR)-mediated non-genomic effects and - as achieved at very high concentrations - non-specific non-genomic effects.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Glucocorticoids / therapeutic use. Spondylitis, Ankylosing / drug therapy
  • [MeSH-minor] Arthrography. Disease Progression. Dose-Response Relationship, Drug. Drug Resistance / drug effects. Humans. Immune System / cytology. Immune System / drug effects. Injections, Intra-Articular. Pulse Therapy, Drug. Receptors, Glucocorticoid / drug effects. Receptors, Glucocorticoid / metabolism


61. Oliveira-Ferrer L, Wellbrock J, Bartsch U, Penas EM, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G: Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway. Mol Cancer; 2013;12(1):144
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.
  • Microencapsulated PAE-cells producing these inhibitors were applied for local therapy in a subcutaneous glioblastoma model.
  • CONCLUSION: Our data indicate that integrin-targeting factors endostatin and tumstatin act additively by inhibiting glioblastoma growth via reduction of vessel density but also directly by affecting proliferation and viability of tumor cells.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Brain Neoplasms / drug therapy. Cell Proliferation / drug effects. Glioblastoma / drug therapy. Integrins / metabolism. Receptors, Prolactin / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2012 May;14(5):420-8 [22745588.001]
  • [Cites] Cancer Lett. 2012 Dec 30;326(2):161-7 [22902505.001]
  • [Cites] J Cell Biochem. 2000 Apr;77(3):455-64 [10760953.001]
  • [Cites] Nat Biotechnol. 2001 Jan;19(1):29-34 [11135548.001]
  • [Cites] Nat Biotechnol. 2001 Jan;19(1):35-9 [11135549.001]
  • [Cites] Neurosurgery. 2001 Jan;48(1):151-7 [11152340.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):380-9; discussion 390 [11504114.001]
  • [Cites] J Neurosurg Sci. 2001 Jun;45(2):70-4 [11533530.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(1-2):79-86 [11831651.001]
  • [Cites] Mol Endocrinol. 2002 Apr;16(4):774-84 [11923474.001]
  • [Cites] Glia. 2002 May;38(3):200-14 [11968058.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27872-9 [12029087.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4263-72 [12154028.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4622-8 [12453880.001]
  • [Cites] FASEB J. 2003 Feb;17(2):321-3 [12475896.001]
  • [Cites] Curr Drug Targets. 2003 Feb;4(2):123-31 [12558065.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4766-71 [12682293.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3598-604 [12839947.001]
  • [Cites] Neurosurgery. 2004 Aug;55(2):426-32; discussion 432 [15271251.001]
  • [Cites] J Urol. 1985 Jun;133(6):1112-20 [4039764.001]
  • [Cites] Endocrinology. 1985 Nov;117(5):2040-3 [4042974.001]
  • [Cites] Life Sci. 1985 Dec 30;37(26):2569-75 [2867449.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):154-63 [8317546.001]
  • [Cites] J Neuroimmunol. 1995 Mar;57(1-2):143-53 [7535788.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):144-9 [8630922.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Nov;55(11):1143-9 [8939197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1246-51 [9990009.001]
  • [Cites] J Med Chem. 1999 Aug 12;42(16):3033-40 [10447947.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Drug Resist Updat. 2004 Aug-Oct;7(4-5):289-300 [15533766.001]
  • [Cites] EXS. 2005;(94):95-112 [15617473.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):539-44 [15700312.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):665-9 [16021573.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1312-7 [15931265.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11331-40 [17145879.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):543-53 [16862169.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Neurochem. 2007 Oct;103(1):259-75 [17635673.001]
  • [Cites] Oncology (Williston Park). 2007 Aug;21(9 Suppl 3):6-12 [17927025.001]
  • [Cites] J Urol. 2008 Jan;179(1):326-32 [18006013.001]
  • [Cites] J Neurosurg. 2008 May;108(5):979-88 [18447716.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e23 [18684337.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:86 [19114005.001]
  • [Cites] Carcinogenesis. 2009 Aug;30(8):1298-304 [19443905.001]
  • [Cites] Med Sci (Paris). 2009 Oct;25(10):775-7 [19849969.001]
  • [Cites] Br J Cancer. 2010 May 25;102(11):1555-77 [20502460.001]
  • [Cites] Mol Cancer Res. 2010 Oct;8(10):1413-24 [20826546.001]
  • (PMID = 24257371.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Autoantigens; 0 / Collagen Type IV; 0 / Endostatins; 0 / Integrins; 0 / Receptors, Prolactin; 0 / type IV collagen alpha3 chain
  • [Other-IDs] NLM/ PMC4176123
  •  go-up   go-down


62. Gratieri T, Pujol-Bello E, Gelfuso GM, de Souza JG, Lopez RF, Kalia YN: Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. Eur J Pharm Biopharm; 2014 Feb;86(2):219-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle.
  • The objective of the study was to investigate the iontophoretic delivery kinetics of ketorolac (KT), a highly potent NSAID and peripherally-acting analgesic that is currently indicated to treat moderate to severe acute pain.
  • It was envisaged that, depending on the amounts delivered, transdermal iontophoretic administration might have two distinct therapeutic applications: (i) more effective and faster local therapy with shorter onset times (e.g. to treat trauma-related pain/inflammation in muscle) or (ii) a non-parenteral, gastrointestinal tract sparing approach for systemic pain relief.
  • Subsequent experiments, in male Wistar rats, investigated the local enhancement of KT delivery to muscle by iontophoresis.
  • Iontophoretic administration for 30min was superior to passive topical delivery for 1h and resulted in statistically significant increases in KT levels in the skin (91.04±15.48 vs. 20.16±8.58μg/cm(2)), in the biceps femoris at the treatment site (TM; 6.74±3.80 vs. <LOQ), in the contralateral site (NTM; 1.26±0.54 vs. <LOQ) and in plasma (P; 8.58±2.37μg/ml vs. <LOD).
  • In addition to increasing bioavailability, iontophoretic administration of KT showed clear selectivity for local delivery to the biceps femoris at the treatment site - the TM:NTM ratio was 5.26±1.45, and the TM:P and NTM:P ratios were 0.75±0.32 and 0.14±0.04, respectively.
  • In conclusion, the results demonstrate that iontophoresis of ketorolac enables local enhanced topical delivery to subjacent muscle; this may have clinical application in the treatment of localised inflammation and pain.
  • [MeSH-minor] Administration, Cutaneous. Animals. Drug Delivery Systems / methods. Humans. Iontophoresis / methods. Kinetics. Male. Pain / drug therapy. Permeability. Rats. Rats, Wistar. Skin / drug effects. Skin / metabolism. Skin Absorption. Swine. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Elsevier B.V. All rights reserved.
  • (PMID = 23791718.001).
  • [ISSN] 1873-3441
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] YZI5105V0L / Ketorolac
  • [Keywords] NOTNLM ; Iontophoresis / Ketorolac / Local enhanced effect / Muscle / NSAID / Topical delivery
  •  go-up   go-down


63. Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ, Goldman MD, Tybor AG, Weichselbaum RR: Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol; 1989 Jun;7(6):761-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both drugs also act as radiosensitizers.
  • Of 15 evaluable patients with recurrent disease after prior local therapy only one failed to respond; six had a complete response (CR), and eight a partial response (PR).
  • Of 17 evaluable patients without prior local therapy, 12 had a CR, with no patient developing recurrence in the irradiated field to date; five patients had a PR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / administration & dosage. Head and Neck Neoplasms / drug therapy. Hydroxyurea / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / drug effects. Combined Modality Therapy. Drug Evaluation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Stomatitis / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 2715806.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] U3P01618RT / Fluorouracil; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


64. Friend DR: Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther; 1998 Jul;12(7):591-603
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease.
  • Inflammatory bowel diseases are treated in some cases by local administration of anti-inflammatory drugs.
  • Local delivery of drugs in the colon following oral administration may lead to improved efficacy/side-effect profiles and may improve patient compliance.
  • This review covers a number of issues important in the design of oral delivery systems of glucocorticosteroids for local therapy of colonic inflammation.
  • These conditions include variations in local pH, transit throughout the gastrointestinal tract, the potential role of gut microflora, and drug dissolution in both the healthy and diseased large intestine.
  • [MeSH-major] Glucocorticoids / therapeutic use. Inflammatory Bowel Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9701522.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 51333-22-3 / Budesonide
  • [Number-of-references] 120
  •  go-up   go-down


65. Baum M: Biological considerations in the treatment of breast cancer: the "fall out" from clinical trials. Bull Cancer; 1975 Oct-Dec;62(4):391-400
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recognition that host factors exist which may place a constraint on the spread of cancer, and that haematogenous dissemination may occur long before the tumour has reached clinical proportions, has shaken the whole basis upon which "radical" cancer therapy is based.
  • Prospective randomised clinical trials designed to determine the most effective local treatment have incidentally produced biological "fall out" which has thrown additional light on the behaviour and nature of breast cancer.
  • It transpires that untreated mediastinal or axillary lymph nodes appear to have little growth potential of their own, or is it likely that they act as a reservoir for further metastatic dissemination.
  • It is at last becoming accepted that irrespective of the extent of local therapy, the outcome for "early" breast cancer is predetermined by the extent of subclinical distant metastases at the time of presentation.
  • In order to improve the results therefore, some form of adjuvant systemic therapy is essential.
  • A number of clinical trials are at present underway designed to explore the most effective means of controlling minimal residual cancer following local ablation of the tumour.
  • [MeSH-major] Breast Neoplasms / therapy
  • [MeSH-minor] Aged. Clinical Trials as Topic. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Research Design

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 764902.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


66. Dhingra K: Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer. Cancer Invest; 2001;19(6):649-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
  • It has been conclusively demonstrated to reduce the risk of relapse following definitive local therapy (and systemic chemotherapy, when indicated) of invasive or noninvasive breast cancer.
  • The ability of tamoxifen to act as an estrogen-agonist or estrogen-antagonist in a tissue-specific fashion has led to the concept of selective estrogen-receptor modulation.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Estrogen Receptor Modulators / therapeutic use. Receptors, Estrogen / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. RALOXIFENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11486708.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen; 4F86W47BR6 / Raloxifene Hydrochloride
  • [Number-of-references] 67
  •  go-up   go-down


67. Diel IJ: [Therapeutic value of aredia in treatment of breast carcinoma]. Med Klin (Munich); 2000 Oct 15;95 Suppl 2:9-18
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • THERAPY: There are 2 treatment options--local and systemic.
  • Local therapy includes radiotherapy as well as surgical and orthopedic measures.
  • The 4 pillars of systemic treatment are hormone therapy and chemotherapy, antiresorptive therapy with bisphosphonates and treatment with centrally and/or peripherally acting analgesics.
  • It is therefore all the more important to start appropriate therapeutic measures in good time.
  • Rather than replacing antineoplastic therapy, this class of substances supplements other treatments.
  • Once started, bisphosphonate therapy should be given life-long, even in the event of osseous progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Diphosphonates / therapeutic use

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11089382.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  • [Number-of-references] 65
  •  go-up   go-down


68. Diel IJ, Solomayer EF, Bastert G: Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer; 2000 Apr;1(1):43-51
MedlinePlus Health Information. consumer health - Pain Relievers.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are two treatment options--local and systemic.
  • Local therapy includes radiotherapy as well as surgical and orthopedic measures.
  • The four pillars of systemic treatment are hormone therapy, chemotherapy, antiresorptive therapy with bisphosphonates, and treatment with centrally and/or peripherally acting analgesics.
  • Rather than replacing antineoplastic therapy, this class of substances supplements other treatments.
  • Once started, bisphosphonate therapy should be given for the remainder of the patient's life, even in the event of osseous progression.
  • [MeSH-major] Analgesics, Non-Narcotic / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Diphosphonates / therapeutic use. Fractures, Spontaneous / etiology. Fractures, Spontaneous / prevention & control. Hypercalcemia / etiology. Hypercalcemia / prevention & control. Pain / etiology. Pain / prevention & control


69. Perez-Soler R: Liposomes as carriers of antitumor agents: toward a clinical reality. Cancer Treat Rev; 1989 Jun;16(2):67-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They also have significant potential for local therapy when administered subcutaneously or intraperitoneally.
  • Although liposomal antitumor agents have no established role in the anticancer armamentarium at this stage, the information available suggests that they may improve the therapeutic index or broaden the applications of available antitumor agents and possibly act as carriers for newly designed liposome-dependent antitumor agents.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 2670206.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / Liposomes
  • [Number-of-references] 73
  •  go-up   go-down


70. Kelly MA, Kurzweil PR, Moskowitz RW: Intra-articular hyaluronans in knee osteoarthritis: rationale and practical considerations. Am J Orthop (Belle Mead NJ); 2004 Feb;33(2 Suppl):15-22
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rationale for the use of hyaluronans therapeutically is based on observations that hyaluronic acid is an important component of the synovial fluid acting as a cushion and lubricant for the joint and also serving as a major component of the extracellular matrix of the cartilage, helping to enhance the ability of cartilage to resist shear and maintain a resiliency to compression.
  • While intra-articular hyaluronans are indicated at this time only for the treatment of pain in osteoarthritis of the knee, there are data to suggest that they may also be useful in treating degenerative disease of other articular joints, as well as have an impact on disease progression.
  • The safety profile of intra-articular hyaluronans is very favorable and, because they are used as a local therapy, there are no known drug interactions-an advantage for patients receiving treatment for comorbid conditions.
  • [MeSH-major] Hyaluronic Acid / administration & dosage. Osteoarthritis, Knee / drug therapy. Pain / drug therapy

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15005296.001).
  • [ISSN] 1078-4519
  • [Journal-full-title] American journal of orthopedics (Belle Mead, N.J.)
  • [ISO-abbreviation] Am J. Orthop.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid
  • [Number-of-references] 64
  •  go-up   go-down


71. Kornowski R, Hong MK, Tio FO, Choi SK, Bramwell O, Leon MB: A randomized animal study evaluating the efficacies of locally delivered heparin and urokinase for reducing in-stent restenosis. Coron Artery Dis; 1997 May;8(5):293-8
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results from recent nonrandomized studies suggest that local delivery of heparin or urokinase to the site of angioplasty or stenting results in a lower rate of restenosis.
  • OBJECTIVE: To determine whether local delivery of heparin or urokinase reduces in-stent restenosis.
  • METHODS AND RESULTS: Thirty-three pigs were assigned randomly to one of three groups: controls (n = 9) administered local saline infusion, the heparin group (n = 15) administered local heparin (6000 u/10 min), and the urokinase group (n = 9) administered local urokinase (250000 u/10 min), via a local delivery catheter (Dispatch) at the site of subsequent stent implantation.
  • Prior to local delivery, all of the animals were subjected to balloon injury (balloon:artery diameter ratio approximately or = 1.3) to facilitate intramural drug impregnation.
  • After local therapy, one Palmaz-Schatz stent (mean stent: artery diameter ratio approximately or = 1.25) was implanted within the left anterior descending coronary artery.
  • We found no difference in percentage diameter stenosis (46 +/- 18% control, 42 +/- 27% heparin group, and 37 +/- 20% urokinase group, P = 0.7) and corrected neointimal area (1.06 +/- 0.42 mm2 control, 0.94 +/- 0.29 mm2 heparin, and 0.88 +/- 0.26 mm2 urokinase group, P = 0.7) among groups at follow-up.
  • The activated clotting time rose slightly for heparin-treated animals, suggesting that systemic delivery had occurred, whereas fibrinogen levels did not change in urokinase-treated animals.
  • CONCLUSIONS: Local deliveries of heparin and urokinase via the Dispatch catheter, at the chosen dosages, do not reduce in-stent neointimal hyperplasia in this porcine model.
  • [MeSH-major] Coronary Disease / prevention & control. Coronary Vessels / pathology. Fibrinolytic Agents / administration & dosage. Heparin / administration & dosage. Plasminogen Activators / administration & dosage. Stents. Urokinase-Type Plasminogen Activator / administration & dosage
  • [MeSH-minor] Animals. Constriction, Pathologic. Evaluation Studies as Topic. Hyperplasia / prevention & control. Infusions, Intravenous. Random Allocation. Recurrence. Swine. Tunica Intima / pathology

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9285182.001).
  • [ISSN] 0954-6928
  • [Journal-full-title] Coronary artery disease
  • [ISO-abbreviation] Coron. Artery Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 9005-49-6 / Heparin; EC 3.4.21.- / Plasminogen Activators; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


72. Tagawa M, Kawamura K, Ueyama T, Nakamura M, Tada Y, Ma G, Li Q, Suzuki N, Shimada H, Ochiai T: Cancer therapy with local oncolysis and topical cytokine secretion. Front Biosci; 2008;13:2578-87
MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer therapy with local oncolysis and topical cytokine secretion.
  • Direct destruction of targeted tumors and subsequent induction of systemic immunity is not pertinent to gene therapy but gene therapy is probably the most suitable therapeutic modality to achieve the local and systemic anti-tumor effects.
  • Current strategies for cancer gene therapy in fact consist of direct inhibition of tumor growth and activation of systemic host defense mechanisms.
  • In this process, dendritic cells play a pivotal role since they act as professional antigen presenting cells and are involved in an initial phase of immune responses, either activation of immunity or induction of immune tolerance.
  • Antigen loading with subsequent appropriate activation of dendritic cells is thereby crucial for activated anti-tumor responses, which possibly eliminate even distant metastatic foci.
  • Combinatory gene therapy with oncolytic viruses and activation of host immune system thereby can evoke immune responses against all the tumor antigens expressed by the process of "antigen-spreading" mechanisms.
  • [MeSH-major] Adenoviridae / genetics. Cytokines / metabolism. Dendritic Cells / cytology. Gene Transfer Techniques. Genetic Therapy / methods. Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981735.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Antineoplastic Agents; 0 / Cytokines; 187348-17-0 / Interleukin-12
  • [Number-of-references] 47
  •  go-up   go-down


73. Matsuda M, Omata F, Fuwa S, Saida Y, Suzuki S, Uemura M, Ishii N, Iizuka Y, Fukuda K, Fujita Y: Prognosis of patients with hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization: risk factors for one-year recurrence and two-year mortality (preliminary data). Intern Med; 2013;52(8):847-53
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Transcatheter arterial chemoembolization (TACE) is an essential therapy for patients with hepatocellular carcinoma (HCC) in whom administering other treatments such as liver transplantation, resection or local therapy is not feasible.
  • A subgroup analysis was performed among 24 patients (Group 2) who underwent complete TACE confirmed with abdominal computed tomography (CT) one month later.
  • RESULTS: The patients in Group 1 (men, 59%), all of whom had liver cirrhosis, underwent TACE as the sole therapy for HCC.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma, Hepatocellular / mortality. Catheterization, Peripheral. Epirubicin / administration & dosage. Liver Neoplasms / mortality. Neoplasm Recurrence, Local / mortality

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23583987.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


74. Michaud LB, Valero V, Hortobagyi G: Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf; 2000 Nov;23(5):401-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They act by binding to tubulin, producing unnaturally stable microtubules and subsequent cell death.
  • The optimal dose of paclitaxel is not known at this time, and controversy over possible dose- or schedule-related differences in efficacy still remain.
  • The combination of paclitaxel and a platinum compound should be utilised as first-line therapy of advanced ovarian cancer.
  • These agents may also be administered intraperitoneally for local therapy of metastatic ovarian cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Taxoids

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11085347.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] NEW ZEALAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 147
  •  go-up   go-down


75. Solignac M: [Assessment of a topical NSAIDs in the treatment of pain and inflammation. The example of Flector Plaster, a local bioadhesive plaster containing diclofenac epolamine]. Presse Med; 2004 Aug 28;33(14 Pt 2):3S10-3
Hazardous Substances Data Bank. DICLOFENAC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of a topical NSAIDs in the treatment of pain and inflammation. The example of Flector Plaster, a local bioadhesive plaster containing diclofenac epolamine].
  • [Transliterated title] Evaluation d'un anti-inflammatoire non stéroïdien topique dans le traitement de la douleur et de l'inflammation. Exemple de Flector Tissugel 1% dispositif local bioadhésif de diclofénac épolamine.
  • ADVANTAGES AND INCONVENIENCIES OF TRANSDERMAL SYSTEMS: Regarding the advantages, one notes the reduction or even suppression of the gastro-intenstinal disorders related to the oral administration of non-steroidal anti-inflammatories (NSAIDs), the absence of first pass hepatic effect and the better control of the quantities administered of a strong acting drug.
  • FROM AN EXPERIMENTAL POINT OF VIEW: Diclofenac epolamine has demonstrated a strong anti-inflammatory effect in the rat or the rabbit, with transfer following repeated local applications, measurable concentrations in the plasma and adjacent tissues, excellent general tolerance and the safety of the plaster.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Diclofenac / administration & dosage. Diclofenac / analogs & derivatives. Diclofenac / therapeutic use. Inflammation / drug therapy. Pain / drug therapy
  • [MeSH-minor] Administration, Topical. Animals. Ankle Injuries / complications. Ankle Injuries / drug therapy. Athletic Injuries / complications. Athletic Injuries / drug therapy. Humans. Osteoarthritis / complications. Osteoarthritis / drug therapy. Rabbits. Rats. Sprains and Strains

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15509042.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 119623-66-4 / diclofenac hydroxyethylpyrrolidine; 144O8QL0L1 / Diclofenac
  • [Number-of-references] 13
  •  go-up   go-down


76. Saling E, Schreiber M, al-Taie T: A simple, efficient and inexpensive program for preventing prematurity. J Perinat Med; 2001;29(3):199-211

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, as far as basic means are available for the majority--such as basic health care, monitoring the nutritional state of the mothers and acting to prevent infectious diseases (malaria in particular can cause prematurity)--determined prevention of prematurity should take the form of screening and the treatment of disturbances of the vaginal milieu or genital infections.
  • Regular screening for signs of such a disturbance using vaginal pH-measurements (and if necessary further diagnostics and therapy) makes possible the detection of an "early marker" to prevent prematurity in an effective and inexpensive way.
  • Our prematurity-prevention-program, which has been successful for many years, is based on an anamnestic assessment of prematurity risk, the early detection of warning signs (including regular measurement of the vaginal pH) and, if necessary, the appropriate therapeutic measures.
  • In cases of disturbance of the vaginal milieu, the latter consists of a therapy with lactobacillus preparations or in a combination of lactobacillus preparation with an acidifying therapy which may lead to earlier normalization of the vaginal milieu.
  • In cases of bacterial vaginosis local therapy, for example with metronidazol or clindamycin, is undertaken, and in other infections specific treatment.
  • In a prospective study performed in Erfurt the rate of very early premature births (< 32 + 0 gw) amounted to only 0.3% in contrast to 3.3% in a control group who had not taken part in the self-care activity.
  • According to a differentiated classification of the control group the success of the self-care activity was even clearer: In patients who did not take part because their doctors did not support the self-care activity, the rate of very early premature births amounted to 4.1%.
  • To date measurement of the vaginal pH-value was performed intravaginally using either indicator strips or pH-measuring test gloves.
  • A short time ago we developed a panty liner coated with an indicator strip, which enables reading of the pH-value by just checking the indicator on the panty liner.
  • [MeSH-major] Obstetric Labor, Premature / prevention & control
  • [MeSH-minor] Abortion, Spontaneous / etiology. Abortion, Spontaneous / prevention & control. Developing Countries. Female. Gestational Age. Humans. Hydrogen-Ion Concentration. Infant, Newborn. Infant, Premature. Pregnancy. Reagent Strips. Vagina / microbiology. Vagina / secretion. Vaginosis, Bacterial / complications. Vaginosis, Bacterial / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11447924.001).
  • [ISSN] 0300-5577
  • [Journal-full-title] Journal of perinatal medicine
  • [ISO-abbreviation] J Perinat Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Reagent Strips
  • [Number-of-references] 30
  •  go-up   go-down


77. Angelescu N, Burcoş T, Jitea N, Bărbulescu M, Cristian D, Vlădăreanu M, Mihai C, Mircea N: [The place of surgery in the treatment of locally advanced rectal cancer]. Chirurgia (Bucur); 1998 Mar-Apr;93(2):81-6
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Locul chirurgiei în tratamentul cancerului rectal local avansat.
  • We considered as local advanced rectal cancer (LARC) tumours invading the serosa or adherent to neighbouring organs, tumoral fistulas, histopathologically proved invasion of regional lymph nodes, peritoneal carcinomatosis with or without neoplastic ascites.
  • In 27 patients adjuvant or neoadjuvant therapy was associated.
  • Surgery is the essential therapeutic act of LARC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9656595.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] ROMANIA
  •  go-up   go-down


78. Bulat C, Stoian M, Pădureanu S, Bîşcă L, Blănaru O: [Intraoperative and early postoperative intraperitoneal chemotherapy--adjuvant treatment for locally advanced digestive system cancer]. Rev Med Chir Soc Med Nat Iasi; 2004 Apr-Jun;108(2):403-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Chimioterapia intraperitoneală intra şi postoperatorie--tratament adjuvant pentru cancerele digestive local avansate.
  • Simultaneous intraperitoneal chemotherapy with surgical resection, which is continued over the early postoperative period act on the tumor cells which can be mobilized during the surgical dissection.
  • This adjuvant treatment could lead to better control of local recurrence.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Cisplatin / administration & dosage. Digestive System Neoplasms / drug therapy. Peritoneal Lavage. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688822.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


79. Norris RL Jr: Local anesthetics. Emerg Med Clin North Am; 1992 Nov;10(4):707-18
MedlinePlus Health Information. consumer health - Wounds and Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local anesthetics.
  • Emergency physicians often rely on the use of local anesthetic agents to relieve patient discomfort, and research continues in an effort to develop new agents with improved anesthetic qualities.
  • Eventually, a nontoxic, rapidly acting agent may become available that could provide profound anesthesia of long duration when applied topically to intact skin or wounds.
  • Until the "perfect" agent is developed, physicians can help the patient by making knowledgeable choices regarding local anesthetic techniques.
  • [MeSH-major] Anesthetics, Local. Wounds and Injuries / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 1425399.001).
  • [ISSN] 0733-8627
  • [Journal-full-title] Emergency medicine clinics of North America
  • [ISO-abbreviation] Emerg. Med. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anesthetics, Local
  • [Number-of-references] 95
  •  go-up   go-down


80. Leunig M, Leunig A, Lankes P, Goetz AE: Evaluation of photodynamic therapy-induced heating of hamster melanoma and its effect on local tumour eradication. Int J Hyperthermia; 1994 Mar-Apr;10(2):297-306

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of photodynamic therapy-induced heating of hamster melanoma and its effect on local tumour eradication.
  • To investigate the contribution of hyperthermia on local tumour eradication by photodynamic therapy (PDT) we quantified PDT induced tumour heating and evaluated its biological effect in vivo.
  • The tumoricidally threshold temperature of 43 degrees C was exceeded at 200 mW cm-2 only, revealing a calculated equivalent treatment time at 43 degrees C of about 10 min.
  • Tumours treated by hyperthermia (water bath) at the maximum temperatures measured during illumination at 200 mW cm-2 (45.5 degrees C for 500 s) or animals receiving laser light at 200 mW cm-2 alone showed a significant growth delay compared to controls (p < 0.05), whereas illumination at 100 mW cm-2 alone or hyperthermia corresponding to the maximum temperature obtained at 100 mW cm-2 (39.5 degrees C for 1000 s) did not alter tumour growth.
  • Although a combination of PDT and hyperthermia might act in an additive or synergistic manner, an unrecognized overlap of both effects might complicate the interpretation of studies on the mechanisms of PDT.
  • [MeSH-major] Hematoporphyrin Photoradiation. Melanoma, Experimental / drug therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Cricetinae. Dihematoporphyrin Ether. Evaluation Studies as Topic. Hot Temperature. Hyperthermia, Induced. Male. Mesocricetus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Hyperthermia 1994 Nov-Dec;10(6):867
  • (PMID = 8064187.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


81. Montorsi F, Salonia A, Zanoni M, Pompa P, Cestari A, Guazzoni G, Barbieri L, Rigatti P: Current status of local penile therapy. Int J Impot Res; 2002 Feb;14 Suppl 1:S70-81
MedlinePlus Health Information. consumer health - Erectile Dysfunction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of local penile therapy.
  • Topical therapy has the potential to become a first-line treatment for erectile dysfunction because it acts locally and is easy to use.
  • At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used.
  • [MeSH-major] Erectile Dysfunction / drug therapy. Vasodilator Agents / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11850739.001).
  • [ISSN] 0955-9930
  • [Journal-full-title] International journal of impotence research
  • [ISO-abbreviation] Int. J. Impot. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vasodilator Agents
  • [Number-of-references] 80
  •  go-up   go-down


82. Brooks JM, Klepser DG, Urmie JM, Farris KB, Doucette WR: Effect of local competition on the willingness of community pharmacies to supply medication therapy management services. J Health Hum Serv Adm; 2007;30(1):4-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of local competition on the willingness of community pharmacies to supply medication therapy management services.
  • The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) provides a prescription drug benefit for Medicare-eligible seniors that includes access to medication therapy management services (MTMS) through pharmacists.
  • We theorize that local community pharmacy market competition affects the decision of individual community pharmacies to provide MTMS.
  • We found that local community pharmacy competition affected the service choices made by the pharmacy decision-makers willing to provide MTMS in a manner consistent with our theory.
  • As a result, patient access to MTMS services depends on both (1) patient access to pharmacies willing to provide MTMS and (2) the level of local community pharmacy competition.

  • MedlinePlus Health Information. consumer health - Medicare.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557694.001).
  • [ISSN] 1079-3739
  • [Journal-full-title] Journal of health and human services administration
  • [ISO-abbreviation] J Health Hum Serv Adm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT: Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res; 1995 Feb;58(2):218-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy.
  • In the present study the possibility of enhanced anti-tumor activity was examined using a combination of local IL-12 by cytokine gene therapy at the tumor site, combined with systemic or local IL-2 delivery.
  • NIH 3T3 fibroblasts transfected with the genes for both subunits of IL-12, p35 and p40, were used as the source of IL-12 therapy producing 240 HLRU/10(6) cells/48 hr.
  • In the first part of the study the effect of different regimens of systemic IL-2 delivery with local IL-12 administration on the size and growth rate of subcutaneous MCA-105 murine sarcoma was examined.
  • Local IL-12 alone reduced the sizes of tumors after 32 days from 163 to 26.8 mm2 (P < 0.002).
  • Adding the longer-acting polyethylene-glycol-modified IL-2 (PEG IL-2; 30,000 IU) for 5 days prevented the development of tumors in all treated mice compared to 1/3 mice treated with PEG IL-2 alone and 3/6 mice with IL-12, but this was a highly toxic therapy and most of the animals died.
  • Administration of 60,000 IU of IL-2 on Days 1-5 postinoculation of tumor, delivered with IL-12 gene therapy, reduced the tumor growth rate compared to animals treated with IL-2 alone (P < 0.02) or IL-12 (0.1).(ABSTRACT TRUNCATED AT 250 WORDS)
  • [MeSH-major] Genetic Therapy. Interleukin-12 / genetics. Interleukin-2 / administration & dosage. Neoplasms, Experimental / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 7861776.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Interleukin-2; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


84. Men'shikova IV, Makolkin VI, Sugurova IIu: [Using hyaluronic acid drugs in local intra-articular therapy of osteoarthrosis in the knee joint]. Ter Arkh; 2007;79(5):31-5
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Using hyaluronic acid drugs in local intra-articular therapy of osteoarthrosis in the knee joint].
  • MATERIAL AND METHODS: Sixty patients with gonarthrosis of x-ray stage I-III (mean age 65 years, mean duration of the disease < 7 years) on chondroprotectors and nonsteroid anti-inflammatory drugs (NAD) in a standard dose received a course (3-5 weekly intra-articular injections) of 2 ml injections of ostenil.
  • CONCLUSION: Hyaluronic acid drugs act long, are effective and safe for local intra-articular therapy of gonarthrosis.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Hyaluronic Acid / therapeutic use. Osteoarthritis, Knee / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672072.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


85. Allen BJ, Corderoy-Buck S, Mallesch JL, Crotty K, Moore DE: Local control of subcutaneous murine melanoma xenografts in nude mice by neutron capture therapy. Melanoma Res; 1992 Nov;2(4):253-62
Hazardous Substances Data Bank. (L)-Phenylalanine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control of subcutaneous murine melanoma xenografts in nude mice by neutron capture therapy.
  • The boron-10 located in the tumour cells acts as a radiation sensitizer for thermal neutron irradiation.
  • The nude mouse model can be successfully used to demonstrate that regression and local control of melanoma can be achieved by neutron capture therapy.
  • Control is a manifestation of the high linear energy transfer radiation released after neutron capture by boron-10, and does not result from an equal fluence of neutrons alone.
  • [MeSH-major] Melanoma, Experimental / radiotherapy. Neutron Capture Therapy / methods. Skin Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 1490113.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Boron Compounds; 0 / Radiation-Sensitizing Agents; 47E5O17Y3R / Phenylalanine; UID84303EL / 4-boronophenylalanine
  •  go-up   go-down


86. Barbieri E, Emiliani E, Zini G, Mancini A, Toni A, Frezza G, Neri S, Putti C, Babini L: Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys; 1990 Nov;19(5):1165-70
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients.
  • One hundred of the 182 patients (72 males, 28 females, median age 15.8 years) with localized disease and no previous treatment were treated with chemotherapy (VCR, ADM, CTX, D-ACT) for 15-18 months.
  • Local treatment was radiotherapy (42 patients), surgery (31 patients), or a combination of both (27 pts).
  • Resected patients tended to have a better local control (Surgery 93.6%, Surgery + Radiation therapy 92.6%, Radiation therapy 69.1%).
  • Disease-free survival was significantly related to the volume of the primary tumor (bulky: 33.2%, not-bulky: 57.7%), to site (extremities 54.6%, central sites 16.6%, other sites 40.9%), and to local treatment (Radiation therapy 30.3%, Surgery + Radiation therapy 47.9%, Surgery 59.1%).
  • [MeSH-major] Bone Neoplasms / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cobalt Radioisotopes / therapeutic use. Combined Modality Therapy. Female. Humans. Infant. Italy / epidemiology. Male. Middle Aged. Retrospective Studies. Survival Analysis. Survival Rate

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 2254107.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


87. Siró B: [The intraarticular and local administration of glucocorticosteroid preparations]. Orv Hetil; 2009 Feb 8;150(6):251-60
Hazardous Substances Data Bank. BETAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The intraarticular and local administration of glucocorticosteroid preparations].
  • The author reports the use of short-acting and combined short + long-acting betamethasone injections for intraarticular and local treatments.
  • In this paper the author describes his experiences with intraarticular and local treatments of 214 patients with 965 short-acting, and 416 patients with 2932 combined short + long-acting betamethasone preparations from 1978 to 2003.
  • AIM: To describe the optimal application of intraarticular and local steroid therapy based on the author's experience and according to the literature data.
  • RESULTS: A combination of intraarticular short-acting + long-acting betamethasone injections resulted in patients being symptom-free (48.8%) or with significant improvement (37.5%), while local application led to a significant improvement (50%) or improvement (29%).
  • Locally applied short-acting betamethasone resulted in symptom-free or significantly improved cases (40.6%), or ordinary improvement (40.3%).
  • The short-acting + long-acting preparation was associated with mild side effects (62 cases), while the short-acting one had fewer mild side effects (10).
  • CONCLUSIONS: Intraarticular application of a combined short-acting + long acting agent is suggested exclusively in cases of visible and laboratory signs of inflammation that are limited to a few joints.
  • Initially, extraarticular management of cases is recommended using mainly short-acting preparations, except in protracted cases or when the application of short-acting steroids prove ineffective.
  • Short-acting agents have little or short-term manifestations of corticosteroid toxicity.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Arthritis, Rheumatoid / drug therapy. Betamethasone / administration & dosage. Glucocorticoids / administration & dosage
  • [MeSH-minor] Administration, Cutaneous. Adult. Aged. Arthroscopy / adverse effects. Female. Humans. Injections, Intra-Articular. Male. Middle Aged. Pain / drug therapy. Pain / etiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179257.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 9842X06Q6M / Betamethasone
  •  go-up   go-down


88. Sousa AM, Franco PA, Ashmawi HA, Posso Ide P: Local effect of tramadol on formalin evoked flinching behavior in rats. Rev Bras Anestesiol; 2008 Jul-Aug;58(4):371-9
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local effect of tramadol on formalin evoked flinching behavior in rats.
  • BACKGROUND AND OBJECTIVES: Tramadol hydrochloride is known as a centrally acting analgesic drug, used for the treatment of moderate to severe pain.
  • A local analgesic effect has been demonstrated, but its mechanism of action remains unclear.
  • METHODS: In this study, we examined the effect of local, systemic and nerve block tramadol on the nociceptive flinching behavior elicited by injection of 50 microL of 1% formalin into the dorsal region of hind paw of rats.
  • RESULTS: Local tramadol in higher concentrations (2.5 and 5 mg) almost eliminated flinching behavior during the entire test.
  • CONCLUSIONS: Tramadol presented a local analgesic effect in formalin nociceptive flinching behavior that is different from its central analgesic effect.
  • This analgesic effect, in this model, seems not to be linked to a local anesthetic like effect.
  • [MeSH-major] Analgesics, Opioid / therapeutic use. Pain / drug therapy. Tramadol / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378585.001).
  • [ISSN] 0034-7094
  • [Journal-full-title] Revista brasileira de anestesiologia
  • [ISO-abbreviation] Rev Bras Anestesiol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 39J1LGJ30J / Tramadol
  •  go-up   go-down


89. Rajah KS: Medical jurisprudence in the local context. Ann Acad Med Singapore; 1987 Apr;16(2):380-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical jurisprudence in the local context.
  • Medical jurisprudence in the local context would require the examination of a wide area.
  • Where abortion is performed, the question whether the husband has any right to prevent his wife from having a lawful abortion is discussed in the local context.
  • Some thoughts on the medical (therapy, education and research) Act 1972 are expressed in relation to the living body, the corpse and the parts of the human body.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 3688820.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SINGAPORE
  •  go-up   go-down


90. Kamerling SG: Narcotics and local anesthetics. Vet Clin North Am Equine Pract; 1993 Dec;9(3):605-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narcotics and local anesthetics.
  • The recently discovered endogenous opioid peptides (endorphins and enkephalins) appear to play a role in this system, which is activated by stress.
  • Opioids (narcotic analgesics) act to selectively depress pain-sensitive cells.
  • Opioid analgesics may act via multiple opioid receptors.
  • Classical opioids that act at mu (morphine) receptors typically produce analgesia, increased locomotor activity, cardiorespiratory stimulation, and a decrease in intestinal peristalsis in the horse.
  • Opioids that act at kappa receptors produce analgesia, sedation, ataxia, and minimal autonomic effects in the horse.
  • Local anesthetics depress all excitable cells and can diminish sensory, motor, and muscular function.
  • They do not act selectively on pain fibers, although pain is among the first sensations lost following a nerve block.
  • Local anesthetic activity is enhanced by increased extraneuronal pH, nerve cooling, increased nervous activity, coadministration of a vasoconstrictor or hyaluronidase, delayed systemic absorption, prolonged drug metabolism, and by using agents with high lipid solubility.
  • [MeSH-major] Anesthetics, Local / therapeutic use. Horse Diseases / drug therapy. Narcotics / therapeutic use. Pain / veterinary

  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 8299018.001).
  • [ISSN] 0749-0739
  • [Journal-full-title] The Veterinary clinics of North America. Equine practice
  • [ISO-abbreviation] Vet. Clin. North Am. Equine Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Narcotics
  • [Number-of-references] 46
  •  go-up   go-down


91. Tucker GT, Mather LE: Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet; 1979 Jul-Aug;4(4):241-78
Hazardous Substances Data Bank. LIDOCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical pharmacokinetics of local anaesthetics.
  • The introduction of the new long acting local anaesthetics, bupivacaine and etidocaine, has stimulated an expansion of interest in regional anaesthesia, particularly for obstetrical applications and pain therapy.
  • System toxicity following injection of local anesthetics occurs albeit infrequently, and tentative correlations have been made between the onset of CNS and cardiovascular effects and circulating drug concentrations in both adults and neonates.
  • Amongst other factors, interpretation of these relationships depends upon blood distribution and plasma binding of the agents, sampling sites and acid-base balance.
  • In respect of blood drug concentrations achieved after various regional anaesthetic procedures, the margin of systemic safety appears to favour bupivacaine and etidocaine compared to shorter acting analogues such as lignocaine and mepivacaine.
  • The time course of local anaesthetic remaining at the site of injection has been calculated following intravenous regional anaesthesia and peridural block.
  • This has allowed prediction of the local and systemic accumulation of the drugs following contined dosage.
  • Blood concentrations of local anaesthetics after perineural injection are not closely related to age, weight or pregnancy but may be influenced by diseases associated with haemodynamic changes and by other drugs given at or around the time of regional blockade.
  • [MeSH-major] Anesthetics, Local / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 385208.001).
  • [ISSN] 0312-5963
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anesthetics, Local; 98PI200987 / Lidocaine; B6E06QE59J / Mepivacaine; I6CQM0F31V / Etidocaine; Y8335394RO / Bupivacaine
  • [Number-of-references] 170
  •  go-up   go-down


92. Zhu L, Pang L, Xu LX: Simultaneous measurements of local tissue temperature and blood perfusion rate in the canine prostate during radio frequency thermal therapy. Biomech Model Mechanobiol; 2005 Aug;4(1):1-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous measurements of local tissue temperature and blood perfusion rate in the canine prostate during radio frequency thermal therapy.
  • Local tissue temperature and blood perfusion rate were measured simultaneously to study thermoregulation in the canine prostate during transurethral radio-frequency (RF) thermal therapy.
  • Thermistor bead microprobes measured interstitial temperatures and a thermal clearance method measured the prostatic blood perfusion rate under both normal and hyperthermic conditions.
  • Increase in local tissue temperature induced by the RF heating increased blood perfusion throughout the entirety of most prostates.
  • The onset of the initial increase in blood perfusion was sometimes triggered by a temporal temperature gradient at low tissue temperatures.
  • It was found that the temperature elevation in response to the RF heating was closely coupled with local blood flow.
  • The resulting decrease in or stabilization of tissue temperature suggested that blood flow might act as a negative feedback of tissue temperature in a closed control system.
  • Results from this experiment provide insights into the regulation of local perfusion under hyperthermia.
  • The information is important for accurate predictions of temperature during transurethral RF thermal therapy.
  • [MeSH-major] Blood Flow Velocity / physiology. Catheter Ablation / methods. Hyperthermia, Induced / methods. Models, Biological. Prostate / physiology. Prostate / surgery. Surgery, Computer-Assisted / methods. Thermography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940507.001).
  • [ISSN] 1617-7959
  • [Journal-full-title] Biomechanics and modeling in mechanobiology
  • [ISO-abbreviation] Biomech Model Mechanobiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R29 CA67970-03
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  •  go-up   go-down


93. Bowers DT, Botchwey EA, Brayman KL: Advances in Local Drug Release and Scaffolding Design to Enhance Cell Therapy for Diabetes. Tissue Eng Part B Rev; 2015 Dec;21(6):491-503
MedlinePlus Health Information. consumer health - Islet Cell Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in Local Drug Release and Scaffolding Design to Enhance Cell Therapy for Diabetes.
  • An encapsulating or scaffolding material can act as a vehicle for agents carefully chosen for the islet transplant application.
  • Generating a local oxygen supply from the implant material or encouraging vessel growth through the release of local factors can create an oxygenated engraftment site.
  • [MeSH-major] Cell- and Tissue-Based Therapy / methods. Diabetes Mellitus, Type 1 / metabolism. Diabetes Mellitus, Type 1 / therapy. Islets of Langerhans Transplantation / methods. Tissue Scaffolds / chemistry

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26192271.001).
  • [ISSN] 1937-3376
  • [Journal-full-title] Tissue engineering. Part B, Reviews
  • [ISO-abbreviation] Tissue Eng Part B Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Insulin
  •  go-up   go-down


94. Masuda H, Kim YT, Tyagi S, Chancellor MB, de Miguel F, Yoshimura N: Local effects of antimuscarinics. Urol Clin North Am; 2006 Nov;33(4):511-8, ix-x
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local effects of antimuscarinics.
  • The most common drug treatments for OAB are antimuscarinic agents that act to increase bladder capacity and decrease the urge to urinate during the storage phase.
  • [MeSH-major] Muscarinic Antagonists / pharmacology. Muscarinic Antagonists / therapeutic use. Urinary Bladder, Overactive / drug therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011387.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK57267; United States / NIDDK NIH HHS / DK / DK66138; United States / NIDDK NIH HHS / DK / DK68557; United States / NICHD NIH HHS / HD / P01 HD39768
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Receptors, Muscarinic
  • [Number-of-references] 61
  •  go-up   go-down


95. Puzman P, Terl M, Mukensnabl P: [Videothoracoscopy in local anesthesia diagnosis and therapy of pleural effusions]. Vnitr Lek; 2006 Apr;52(4):321-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Videothoracoscopy in local anesthesia diagnosis and therapy of pleural effusions].
  • Up to-September 2005 there were realized 75 videothoracoscopies, all under local anaesthesia with analgosedation and during the spontaneous ventilation.
  • During the exploration it is possible to carry out, besides the collection of bioptic samples from parietal as well as visceral pleura, a whole range of therapeutical acts - evacuation of effusion, mechanical disruption of adhesions in case of empyema with its subsequent drainage or pleurodesis with talc in case of malignant exudates.
  • [MeSH-major] Anesthesia, Local. Pleural Effusion / diagnosis. Thoracoscopy. Video Recording
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vnitr Lek. 2006 Apr;52(4):304-5 [16755984.001]
  • (PMID = 16755988.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


96. Valle M, Price RW, Nilsson A, Heyes M, Verotta D: CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain; 2004 May;127(Pt 5):1047-60
Hazardous Substances Data Bank. QUINOLINIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
  • Quinolinic acid (QUIN) is a product of tryptophan metabolism that can act as an endogenous brain excitotoxin when released by activated macrophages.
  • CSF QUIN is putatively one of the important molecular mediators of the brain injury in this clinical setting and, more generally, serves as a marker of local macrophage activation.
  • This study was undertaken to examine the relationship of CSF QUIN concentrations to local HIV infection and to define the effects of antiretroviral drug treatment on CSF QUIN using two complementary approaches.
  • The second involved longitudinal observations of a subset of 20 of these subjects who initiated new antiretroviral therapy regimens.
  • The cross-sectional studies showed strong correlations of CSF QUIN with both CSF HIV RNA and blood QUIN levels, as well as with elevations in CSF white blood cells, CSF total protein and CSF:blood albumin ratio.
  • Kinetic modelling of CSF QUIN decay indicated that CSF QUIN levels were driven primarily by CSF HIV infection with a lesser contribution from blood QUIN levels.
  • CSF QUIN serves as a marker of local infection with a wide dynamic range.
  • The time course of therapy-induced changes links CSF QUIN to local infection and supports the action of antiviral therapy in ameliorating immunopathological brain injury and ADC.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. HIV Infections / cerebrospinal fluid. HIV Infections / drug therapy. HIV-1. Quinolinic Acid / cerebrospinal fluid
  • [MeSH-minor] AIDS Dementia Complex / cerebrospinal fluid. AIDS Dementia Complex / drug therapy. Adult. Antiretroviral Therapy, Highly Active. Biomarkers / cerebrospinal fluid. Cross-Sectional Studies. Female. Humans. Longitudinal Studies. Male. Middle Aged. RNA, Viral / blood

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15013955.001).
  • [ISSN] 0006-8950
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5-M01-RR-00083-36; United States / NIAID NIH HHS / AI / R01 AI 050587; United States / NIMH NIH HHS / MH / R01 MH62701; United States / NINDS NIH HHS / NS / R01 NS37660
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers; 0 / RNA, Viral; F6F0HK1URN / Quinolinic Acid
  •  go-up   go-down


97. Muller DW, Gordon D, Topol EJ, Levy RJ, Golomb G: Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. Am Heart J; 1996 Feb;131(2):211-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting.
  • To determine whether sustained, local delivery of hirulog, a potent antithrombin agent, inhibits thrombus formation and neointimal thickening after arterial stenting, silicone polymers containing hirulog were formulated at a concentration of 5.8% by weight and were tested in vitro to determine the rate of drug release.
  • Hirulog-impregnated silicone polymers were placed around the adventitial surface of one stented segment of each animal and a control polymer was placed contralaterally.
  • Intravenous hirulog (4 mg/kg/hr) was infused for the duration of the procedure to maintain the activated clotting time of > 300 sec.
  • In four pigs killed on days 3 through 5, macroscopic thrombus was very faintly visible on the stent struts of one arterial segment treated with sustained-release hirulog but was readily evident in all control arteries.
  • Histologic analysis showed no difference between hirulog-treated and control sides in the volume of neointima (540 +/- 129 units vs 357 +/- 95 units, p = 0.27) or in the average intima to media ratio (0.44 +/- 0.12 vs 0.34 +/- 0.24, p = 0.47) over the length of the stented segment.
  • Late thrombotic occlusion occurred in two hirulog-treated and two control arteries.
  • In this model, local adventitial hirulog delivery at the dose and delivery rate used may reduce, but does not prevent, thrombus formation and does not reduce the severity of neointimal thickening after carotid stent implantation.
  • [MeSH-major] Antithrombins / administration & dosage. Carotid Arteries / pathology. Carotid Artery Thrombosis / prevention & control. Hirudins / analogs & derivatives. Peptide Fragments / administration & dosage. Stents. Tunica Intima / pathology
  • [MeSH-minor] Animals. Drug Delivery Systems / instrumentation. Hirudin Therapy. In Vitro Techniques. Infusions, Intravenous. Microscopy, Electron, Scanning. Recombinant Proteins / administration & dosage. Recombinant Proteins / therapeutic use. Silicone Elastomers. Swine. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 8579010.001).
  • [ISSN] 0002-8703
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Hirudins; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / Silicone Elastomers; 128270-60-0 / bivalirudin
  •  go-up   go-down


98. Mathies H: [The therapy of pain in rheumatic joint-and spine diseases.]. Schmerz; 1990 Sep;4(3):130-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The therapy of pain in rheumatic joint-and spine diseases.].
  • The therapy of pain caused by rheumatic diseases above all must take into consideration the cause of the pain.
  • The so-called disease modifying anti-rheumatic drugs do not influence the inflammation or consequently, the pain directly, but rather through mechanisms before the local joint process some of which are not exactly known.
  • Therefore, physical and especially gymnastic therapy play a major role.
  • If there is pressure on the ligaments and, in cases of vertebral dislocation with overstraining of the vertebral joints, therapy with local injections is indicated.
  • Moreover, fluoride also acts as an analgesic once the osteoporosis has stabilized.
  • In most cases fibromyalgia, which is mostly of a psychosomatic nature, cannot be influenced by medical therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415250.001).
  • [ISSN] 0932-433X
  • [Journal-full-title] Schmerz (Berlin, Germany)
  • [ISO-abbreviation] Schmerz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Jackson SR, Richelsoph KC, Courtney HS, Wenke JC, Branstetter JG, Bumgardner JD, Haggard WO: Preliminary in vitro evaluation of an adjunctive therapy for extremity wound infection reduction: rapidly resorbing local antibiotic delivery. J Orthop Res; 2009 Jul;27(7):903-8
Hazardous Substances Data Bank. CALCIUM SULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary in vitro evaluation of an adjunctive therapy for extremity wound infection reduction: rapidly resorbing local antibiotic delivery.
  • Current treatments to prevent infection utilize surgical debridement and irrigation, and high doses of systemic antimicrobial therapy.
  • The pellet could be used as an adjunctive therapy at the time of debridement and irrigation to reduce bacterial wound contamination.
  • Small pellets containing a binder and calcium sulfate were engineered to resorb rapidly (within 24 h) and deliver high local doses of antibiotic (amikacin, gentamicin, or vancomycin) to the wound site while minimizing systemic effects.
  • Adjunctive therapy with fast-acting pellets is promising and warrants further in vivo studies.
  • [MeSH-major] Anti-Bacterial Agents / pharmacokinetics. Drug Delivery Systems / methods. Pseudomonas Infections / drug therapy. Pseudomonas aeruginosa / drug effects. Wounds and Injuries / microbiology
  • [MeSH-minor] Absorbable Implants. Absorption. Calcium Sulfate. Humans. In Vitro Techniques. Microbial Sensitivity Tests. Staphylococcal Infections / drug therapy. Staphylococcus aureus / drug effects. Staphylococcus aureus / growth & development

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105225.001).
  • [ISSN] 1554-527X
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; WAT0DDB505 / Calcium Sulfate
  •  go-up   go-down


100. Bizer VA, Khmelevskaia ZI, Boĭko IN: [Combined treatment of patients with osteogenic sarcoma using local UHF-hyperthermia]. Ortop Travmatol Protez; 1989 Jul;(7):28-30
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined treatment of patients with osteogenic sarcoma using local UHF-hyperthermia].
  • The results are analysed according to the method of treatment in 3 groups of the patients who had been administered different total focus doses acting on the tumour.
  • Besides chemical and radial therapy and surgical treatment local UHF-hyperthermia was used as a modifier in the complex of therapeutic measures.
  • It has been demonstrated that the use of local UHF-hyperthermia does not increase the risk of metastatic spreading, allows to reduce the radiation dose and by influencing the primary tumour contributes to better treatment results.
  • [MeSH-major] Bone Neoplasms / therapy. Hyperthermia, Induced. Osteosarcoma / therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Combined Modality Therapy. Humans. Radioisotope Teletherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 2812736.001).
  • [ISSN] 0030-5987
  • [Journal-full-title] Ortopediia travmatologiia i protezirovanie
  • [ISO-abbreviation] Ortop Travmatol Protez
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] USSR
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down






Advertisement